var title_f7_54_8032="Cryptogenic organizing pneumonia CXR II";
var content_f7_54_8032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptogenic organizing pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 282px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEaAUwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5zufFXiBbmVV1vUgA5AH2l/X60h8UeIh/zHNR/wDAl/8AGse7/wCPqb/fb+dPegDU/wCEp8Q8/wDE81Lj/p5f/Gk/4SrxD/0HNS/8CX/xrJzg8daaTQBsf8JV4h/6Dmpf+BL/AONH/CVeIf8AoN6l/wCBL/41j9s9qUIxBIBwO9AGv/wlXiH/AKDmpf8AgS/+NPi8TeI5CQmuajkKWObthwBk9T+lYnGO+70pKANn/hK/EP8A0G9S/wDAl/8AGj/hK/EP/Qc1L/wJf/GsaigDZ/4SrxD/ANBzUv8AwJf/ABo/4SrxD/0HNS/8CX/xrHIGeDml2nYGx8pOB9aANf8A4SrxDj/kOal/4Ev/AI0f8JV4h/6Dmpf+BL/41j0qg9h70AbI8UeIj/zHNR/8CX/xqeLXvEsnTXdQA9TdPWJEuWFb+m2jyoAOB1JPSgCVdS8Ut0169+n2qTinrfeKmIA1+8yf+nqStOys1jnXO2QAglSMZHpWwLaB5ML5qZ6BgKAMG3TxhPjZ4guRk45u5R/Stu08MePLqAzReJTsUZOb2bj/AMdre022gBVdob3xjP5V22mXCJCqxxtFn5drdM0AeQXej+N7V9r+JJCcZ+W8m/qKpJB4xc4XxDcY55+1y44/CvQ/GchEwSKJpHK8L+dcK9rqk8gVI5FUjG0nHH0oAs2GgeOb6PfD4lIXOPmvZv8A4mrMnhTx6gOPE27Azxezf1Wuu8IWGpxWJjKqQDhvmB7Vq6sZVttoiZCwwSTgD60AeS31l4zs0LS+Ipjg4wt5Kf6VQkn8WoOfEF2fpdyV3twIZIbhYI1kkRctI7YHXGFHc1h3Dw2vDRrv/U0Ac1NeeLIUDPrt6Aeg+1SZqqda8TAEnXr7/wACpK1L6781y00aKv15/KqFwbZl/dTAHuMYxQBTk8SeI0bB13UD7i5f/GmHxP4i3ADXNRJP/T0/+NVXKtkFuD7VVZcHHagDT/4SrxD/ANBzUv8AwJf/ABpP+Eq8Q/8AQc1L/wACX/xrJK88U3HNAGx/wlXiH/oOal/4Ev8A40f8JV4h/wCg5qX/AIEv/jWOBS7eM5HpigDX/wCEq8Q/9BzUv/Al/wDGj/hKvEP/AEHNS/8AAl/8aylQsrY6jk0qr7UAav8AwlPiL/oN6l/4Ev8A40f8JT4i/wCg5qX/AIEv/jWaEJqeKxnlxsjc++KALn/CUeIv+g3qX/gS/wDjR/wlHiL/AKDmpf8AgS/+NNGlzIuXAXHPPNQNZFO5xQBYbxT4hAydc1L/AMCX/wAa9t+Cms6pd+E7iS61G8lk+2ONzzMxxsT3rwC7iMcYJ9cV7h8Cv+ROuP8Ar9f/ANASgZ4Vd/8AH1N/vt/OpZV2swyp/wB05FRXf/H1N/vt/OtabTHiyX6c4OOKBGURQOD6Z45HSrb2hUA5yPam+RiJvkLPkbSDwBznj8qAKm04pcEg88ccVOIWJ5GKsrZbkL8AZxjNAGdjPQc/zoK9avLZFj8jHOeOKDYTDJwSPagCjtoZdpIyDjjI6GpzA4PzKR9RU09q8drFIw/1hOM+g4oAogU4DipNvAxnOTkfypuDigBCOlCg9KkSMlSeg/nVu2tDK/OEjHLMaAH6bCocPIMnsDXVadE5VSc7B+AxXO/a4ISBCGdh3I4qK71SeQBdzbQOgPFAHbQMgc+Su4j3FalteXYfypbaN09Bya8uW6lI4JAxj5eM1q6VPOJUkWdkkHQ56UAempKp2+W3lMTypHStnRrqfzmTcQnbPPFefafq11FMIriMTRqeWHX8667RL1RPHPauSpH3TwDntQBY8Y3k0MnmLhVZQAQOvsa5TT2lutRiEjtj7+M9cc4rX8bT+ZcDeWVsA4PauEW5vIrsPFDIXHKZBH40Aey6b8tss64VpBuKg9SCQT+OK0pII7yxiQEkuxLE9q4Xwre6xflxLbKmFARF6ACu0t4byKPb5XzcZxjg5oA5XxC0GnIUjC7vULwPYV5xqt8fMZmbZnsOSfqa7DxjI8ZdpHV5BkYHRTXmV2GaY72LMaACe6Vh8ikH1zVYTkNnGaikPbP4VGT2oAsNKCdyjB+lJvDIM53ZOfT2/rUBcseeO1IO9AFpUR+MYPtSSW5BIU7hng4wagVmU5Bra0hkvZkglG1iQBJ0x9fagDHMZBwRT44Hc4UE16dbeAhMo+0M027hGgHAPvWvp3w6lhcC+Ajj6qF6MKAPLtH0+Zr6ExxNIQw3ADPHfNeg3/wxNvMJ5JhHbyjekY7jvg121rokNmojsIVXg/Nt611+j2EN1oxt9Xl2tBysmcuF7Y+n8qAPGIfDdrboDb2uTnALjJJrStvC95dkrGjYx0ROBXpN1a21t89lafbD/DcMf3ZPuByDWLc6lrVwTE832YA8pCuwUAchceB54fmuMxg9mGc/lWHP4b/eeWgLHpwv869NstI1S5Jfzp1jPJd2raj0uVIhGkCMuOXYYJ+poA+cvGWgXGl2Ec8xAR5QgXv0J/pXpfwK/wCROuP+v1//AEBKo/HKBIvDlqVIZjeJyOR9x6vfAr/kTrj/AK/X/wDQEoA8Ku/+Pqb/AH2/nXrE9n9pgFt5bLAmcLwce+fWvJ7v/j6m/wB9v519FabawXsKvChyR2oA8tn0kozJKCu09hxSQaZGrKeQa9Nu9BZ924E556Vg6jozQyYVcNmgDDg0m1mAWdCMZyyjmrF1omlWsIM96yKR8uY8kH3xVqBLqE4RdyZxjHWtO3tILuPYYJAzcFcbgaAOWt9EhlfNndW8464V9p/WrS+H7iMj9w4Jx0Ga17jwFdz3YTTYy03aM9R+Partp4Z1PQpQ91qAiuB/CJS4X8O5oAoWfhc3JWCa2DyPweMFai8ZeDoVubaDTjlYIsFCcbie/wCmfxrvNM8QtbqIpkWZWxukYDzH+uOg9qjuJLbUruSeIlWbkA9vT+lAHhd5olxauUnhZW9ccGmW+g3M5zGhI/ma92OkC+IiliV0xlnHIUVBrGg2ek2DXMbhYEHyxfxPjsP8aAPE5tMeyjMl0uFXv2+grGuLreCE+Va1/EmpXWo3hNyvlRqf3cQztUf1PvWOId+QFOfagCuWb1x9KATkHNSyQlMbiPzpR5YTnJNACIOCc1et7p4MgAMB6iqseAc4wOx9aktV8yZUZSQxA4oA67w5eQOhVxhznj2rUa9t4bmOGKYb9wPy8Y+vvWRd2cUUEXkS7GI2JuGN3+eahNnItuvmRlZR/wAtPWgDsNSvJrwIp/eMynBwPfvXPp58p2Qu75OAD19hn1ptheStpaxO7rsJUgdu9Gm36WN/C5XcoYHOelAHb+HreePVpMP0X+ldvY26SW8oaTbIGzhzjj1rmNDuYXubcQyeYWJchRjH411sgJtWBTZuGfm7igDyvxvFClwULhn+bIXoeepNeZ6j80rkLsFeneJ9Ouprq4fy9saknnufauH1CwU/NNKodf4FGSaAOWdSOKbjB561oyRYBEacdqfb6bczsqrA5Zjx8vWgDOMLZGAeRkVPHZllDFsGul0/w7evuDW4UYzmQ4PvgV0WnaPZRW0dxcRq7Z27SfbjigDz+OxUsyjcWB9M1rWOg3U0iliqR5GWzyB9K6O91DTLYxxfYFViTuZDwMdKn0h9Nd3a4uQgfjEnAzQB33gHVYtM2WUpVm4UPJ39jXpnlW1zbMZ8iI84/ijPqPavn460llKqRxpcwj5Q5PA+hru9D1K5mVC1xuUAbVY8/T3FAG1q2oPZSPbwKNwHDgcMPUGsCK5lW+WWSQuCcMO2D1rq7q3h1PT1KKFkQfL/ALJ/wrmZrJlkAcFGBwQexoA67wqki3BVCd27sOo+letWFjp8kcX222ge5I4kSMZQV534egMdj9oUfOyKoP8AOvR9NUfYIccyMM5HpQBBqmiRwqZIbWKRccSdf07Vx2paXLcbg7uvJAHb8q9Ss/NgizKMq56EdqSfSrS5/eBcZ7DpQB8k/tFaO2n+CLGbIKnUETIHfy5T/SqHwK/5E64/6/X/APQEr039sbT4rP4W6X5QAH9sRL/5AnrzL4Ff8idcf9fr/wDoCUAeFXf/AB9Tf77fzr6ssdI8q5RoE2E/eQdDXynd/wDH1N/vt/Ovu+z01EQFQCx6560AUbTRIZIkMnzSDnA6Ef1qObwvaXbNvhVc8ZxXW6BYu05icDao3AntWt9mtg5AZW5xjbQB5RB4OmacpHbbkDYACf4Vup4Tt9LiWTUJVjPUQx8sfbPQV30tzFp6O8hCcDnsg9/U1x+sNDKxnWZ5w3O/GCfwoA5HxfqTx6Ttso/skYfb8h+Zx3y3WvNvtMr5WcFkJ+8eo9813vi6MSwgRg7Cen0rhp7dt2QM4oAZ5ISXDYJGeR0pbGOU3GLf756EdqvJbNJBHwc7duPXk10GnafFpsDz3I+7ycnkt6D6DrQBYj1G00fT0kvcJGozkdZD/hXlnjXXJtXvCFYlOyx9FHoParvi/UpdUuihY+SOOBnbXFQP5Rllgfavdj0wKANYaLkwyT7Z9+Pkx2+tQ6naWEUgjnhWyRgSdp5b6CrGm+K7C0tjGYZHYD/Xj/2Uf1rlbq8j1C6kkDuck43n5qAKWow2oci0Z3X1kGKoQwSykhFUkelbd5ZqIUdDjPU+tVIU+zy7l79eO1AFMWd0f+WT/lV2wtbqOQv5WXTn5h0rRaKaaNZlUsmMA47VWiV4s5BBP8J9KAGyXck8y+aThOMA1u6Jdm6mjtyd8XXnrmseLS5w6kgbic46Vc0i2ks5o3l3oVfBPUHFAHUvBAUVHgwHJySOcgVFZqbeV4JLSBwjHqO9dTbyLJbxMFRgy5UlQcdzVS406RplmchmYk5+lAHY+Do9k0ZFvGuFHb2ru7e0+0I7TKNvAwBzWB4TsWA8wkqV+XkenSuuto3hlzH0IHvmgDi/EumbS5mUZGcZHX0ryLWpbS2kbMEDPkkDZ3969h+I00sQlYH7wH3fT+leCXUc76iyzY+ds5PH40AJK/nXKFo44Rjd8ijA/CtfSwsnmOHG3BHmMeQPSnWWjT3URYFNv8UnPy1PY29rpltJDPmdySTjgN6UAaVjYYgcNcKwVcq2eorndR+zaNKd8pdsZ4POff2pur6pLbW80SlUVlyqRHoPrXC3Fz50jOzPlskknOaANDX9YivJFa3iVNoxWXDO0hJclu+DTPswY5XOO9X20uWCFZEIZWwfTFAE9rdmOdBGBtyCQ/I/KvR9I1KzvhCLVvKvRj91nCv9DXmNtGgbdLnap5rXtZniki8hATkDkYzQB9CeG5zeq0brtnQYIx94eh9617nS1uR5gjHnIOePvr/jXL+DtWgSyiiuyFucYD55XPY+or1HTYPtFup24nTn6igCno1v/wASdFP/AD04+ldTpuURBjhTxVOOzVLdtnCs24DHfuKuQEqBtHA6UAXHkmSTzA7bge5yD+FbmnTCeIOnHZl9DWHG4f7wJArVsV8mYFeFbgigDxT9tb/klmlf9hqL/wBET15L8Cv+ROuP+v1//QEr1r9tb/klmlf9hqL/ANET15L8Cv8AkTrj/r9f/wBASgDwq7/4+pv99v51+gVsMMDzt+tfn7d/8fU3++386/RC3i82TrgjmgC3bn92pQdDzV2xtxNchzkqOTimW0QEThegGSatWpNvp11OT0XAP1oA43xRK13f+WhYwI//AH01ZEilEYMWA7VuzxH75HfPIqhOiKSSefTHegDlNUgLoqgAAEnrWDJprl9oQ898V2dxArO7PnH61Bp9j5z47uevoKAM2w0oQwxSyAKE5yR065P4VzXi28e53QwAKi/w9do/zya7zxa62WnrHEQGwPlP44B/ma8uvb2OENLOxKk468u3pQBzeq+XaWjvP8sYIOOpJ/qa8613UftMm2BBDBnIQfzPrXYeJ43urZp48MgU/Lk4X/P+fSuAlhkkyQCQOtAAs5C4KjHfio1iLHcAAhPc4pBtGFYbialDBCNxHNAGtpsrSW8kLysw7IelaNm1tDGq3EagZ5ZVzgVjWE6W03nBA4xgBjgVA97JNKcHA6ALQB2VwdyxCCYNEqckDAX8Kq2kTG6RmwxB3DcvX8K523upICpQncTgg9K3tK1CY6pb/ai21SOCDn2zQB3Wl6RBcmOQQbXlHJxnB+lU4/DyT3zKNxRshQoPPPWugn1uLS7BfLiRw+AGCn5T6+9RWWvxtdKFkUZ+6h4AFAFq00i4thD+8jk64VfvAe4/StK30W6Z5SNoGPlU4IH1qWcLc6nGsYKgcZHHGM1uw2m64wCH4XJHr/hmgDo/DWkytbZGEV8E5PX8a2p7KSCM9CB0wav6DZiLTIuACRjFXJk3QuqEBiMCgDzvxXpi31mWnkAIUllXk15BrS2OnzCZ182YAhY+lev+KopbZplWZY2ZCeRweOvtXzn4t1Z/tMsKTq9wrYOe340ADaxPdXQVneKJedo4VR3471Qu9QCysyXQbnHJycVy1xdTMux2JH1quk2SQeKAN+9vYZyEQys2Du4xu/OsMlMEBH9vatP9zJYEqf3o6H/Gs1kbaQD09O9AElpKkUn71WIIxxW7Mwe2Elu7gMPlLpgEDg4P1rnjCysA33vSul0dlt7XyJIizk898UAZeyRGJVCVPUjnNdFpVxGzxC4jHlr0kA5rnry5beRGvlMpIBWtDQr9iZEvI/NHG0qOR9R3oA77TLp4YjNLGGIbapPAx9Oxr2T4da60tzb284/duNiHuh9D7V5XpNodStYHjVfLQ4Vojx9D7122hQSW0sZhjfdkF0Xt7igD2+eHNk5AIZGy1QWy5BUDp0qzoFwLrTlZ8E7cMKhePypyMcZ6+1AFiFBnp71o2p5C9qrxRjt0q1CMN+NAHiH7av8AySvSv+wzF/6Inryb4Ff8idcf9fr/APoCV6z+2n/ySrSf+wzF/wCiJ68m+BX/ACJ1x/1+v/6AlAHhV3/x9Tf77fzr9ILWNZIi0J+VuSfX8K/N+7/4+pv99v51+jWm3ESuYg4djyABQBrQw7IGAXqPSlu0zpk0SH+AH9RVVp5DyGwg7Vct2Dx4PIIxQBzV0v7lQPpxWVLGeoz+NbVwuCV7A496qvB8rcD3NAGFexEhVXjnH1q3plvtQkZyTtH4Ut2pMgwM45rShT7Np5nYgbEJBP6k0AeX/EXVo7aVvMJMUedxHc+n1rxLXtSa9u2l2lYgRsC87BXZ/EPUvtV8zkP5CbgB05J6/U1x8UFvsDP8smQUj9D3zQBHYgyOzSsRE/OzP3zxkH0rI1RcxukaCKFjz2ANb09uqRiYykMAT5DdW+vp/WuSurmWWfN0+NvRV6L+FAGfPAUxlCh7k+vtTFhyMspJ9TVu6kE8ALHPO3dnJGBxxUUL5iMfJOcZoArtKVJTI2+1RbsE47HrVx7YFlBIU98c1aa3itI1eNS0hOBu5FADtKja5yCm6THy/Wt6zneC+QSqWMXAJHf0qrp1zcfbOHKSnB44ya24pZX1GETBpADuGVzzQAXFzc3DjdE5CkEAZrVtNMkMSXEqDjnj2rbitxLmXbwxG5cYxW/Z6Yrq8jeYi47dfyoAp+FwZ7pJ3JZF4AA6Zr1TQ7ZW2hlXrnJ9K5bw3ogQ4gb5MA5I5zzXonh3TimHkclwMGgDo4IdlugA4HSor2LMBYDnHrWqluRAvbgVXkti6kL6YNAHkPjZDK7woWO1CxOM5NfLvjKxurLVHeSFgJTuz1H0r7G8SW6RvIFcF2J3ZFfNHxQmaEGJwpDynH4d6APMSjHaWz8w71XljLHIII6cVozAtEx2jjqM1HBbgx+Y7rjOMdc0AVId0RKlsA8Vt2mlm7/eJKQVxzt49uaoMsbIuG+YNgZFdRaNY2mmIWumEuSSvl8H/OKAKWiaHNc3ijeGOQDkcYzXQnw/NCZzbyx7NvDA8Gq9ndQXVvIIboRlRuO4EAn/AA9qjjkKyHzrjJQEqqn5VPr70ARy+H2uLNsyBZ15XeuMiqlpp8kFyA5VSB2Ndh4Z1KSeJt0QuNhCgEdq6eXw/aujSzRRwFVwCenuD6UAYfh22vLIRy2km0MwyByGr2fws8c8wmigETgfPGeoPt6ivNbG5trXAJxsGMg/L9BXbaPqBJiki2lhhlXd8340AevaIixq5VAqkjcvpmrt0isFJ6r8pPSszw7drdwlwm3zBhlJ6H/CtiWMkOhPDICKAHR7cAjpirMQBbis6BiBknitC1J81fQ0AeHftq/8ks0r/sMxf+iJ68l+BX/InXH/AF+v/wCgJXrP7apz8LdK/wCwzF/6Inryb4Ff8idcf9fr/wDoCUAeFXf/AB9Tf77fzr79t5jFKrjgqfX9K+Arv/j6m/32/nX3qshZh3oA6y3bzIQ4ONw4Bq5asNpAHGax9JkPkhR1B+talqfnwT3oAoTrk9BkMRTJY/3e7H5d6t3SbZ2z0J9KJCqwDPXBxQBjLbG4nyigdqofEK9Fnoq28PDSgE467R2/Guo0+EHcxwBjA/rXn3iyX7dqks0hPlRnYqjvigDxfWIoFuJTM7K7ZKb+gBrjtXkeBvOj2uw4wOg68muy8Xm3inkRnU3PLxE8gA+v+Fef3+22uSEYuXOck880AVrmeVVkeSQmaVfmyeRWPOGlbauWcd/WtcxpIN0hIOQW78VVeJpJtltlm/hCc5oAoJG0EmJ1PTODxg1fFoVSM5zG5xn0P1qrKjLIRcb5JfQDr9a1nc3VjHGR8ic7Bxs9qAG3FrbWLRF5hJKRx5fIH1JpJ76P7GAixq6nG4rk4+tZEgkfcrB/l5HpTTkIRnGcHB70AWVuHaX/AFjAkbeOwrasBchYc3DkZ+bLdBXPqzIVdlAycDIrQFw8smFDbQADjvQB6P4T1KSK6C72kH8OR0Hue9elJqSkLGhSSRzg4GCOK8ZsEubdI5IICSMZPpmuj02aafUVMLMwiOGOOlAHuHg+FLnDyNhg54744xXfwwhSWRcA8ge1cT4CtCXBZTubBz9K9KkgChSO4oASFm8pRnkinDGw565z9KQIUKknPGKneNQQfXmgDznxZGpeccHKkn2xXzH8XilzPC9uRtRjwB1HrX1N4qt0lmdmU9wfSvnT4j6TFdX0kMQAkKkrjpQB4wnyjDuOeK0NLWPcY2JCk4yelW7bwtqE0+11C465r0Cx+Hx1CzH2NCWReWcgHPrQBwdusct8yrArRsQo475rcvPDzCEM+3gklAMkGur0LwmdPvQbqDY8YwyAgj6j8q6vFuyqi2RZx0UYwOOtAHmug6S0hECQYhkUqzNjAOen9ayvEmlf2fLJHuVSeh7tXpa4htZZPIEXzbigHIP+RXIatYG/YvLMcA8cc/SgCHw7fPp1vGqqGhI3MP4j7k10mlX51S6IWXYgXiKU4JP171y8aR/ZbhH3xKMAk9+PWtyy0JdRtIZft4+Vcsi9x9aAOusUtd21rWNjnDFsEn8K6qzsoY41n07aSeAoHX1//VXB20rWjwwTEyR4Chh99ff3Fej6F5drZebEwaEjhgOR+HY0AbXhu8nt9VtyxJU/K47Yr1F0Hlow5wOPpXkcbSCeNkDEkZYY/WvW9PfzLKHOOUAP4igDPRdrMM55OKv2Y/ffQZquFxNICOQSKt2w+dsZGMCgDwn9tM5+F+l9P+QzF/6Inryj4Ff8idcf9fr/APoCV6l+2cc/DDTP+wxF/wCiJ68t+BX/ACJ1x/1+v/6AlAHhV3/x9Tf77fzr7nhZlYAdO+a+GLv/AI+pv99v519vxyc9aAOk0Of98VzyRkY9q6JQRMGPAOCa5HRm2XCFe55rsQx+XH6UAPvF3gNx6Zqo4JwBngY6dK0W+aMj8arW6lrgFumaAG3SeVYyqOoTb9PWvH/GOpLp8UkxXLA7VTPDHt/jXsuthhpjkYG7JJPpXzx41u31G82RKWiyVjGPzNAHnmsySam8m8Kbh2JCgd/Wso2BhYbh5kzdQOQDWxqKNa7/ACXKsB8zevqKp2U8qStJL829f9WTgnHc+goA5/ULZrV/mXZF0ye/rj1rLmmGdlnmGMjkk/Mfqa6DXIzdShwWJXOxAOntisNrOaISsI94HUnqPagBrXckeYzhif4vSrlrcySWxCjC/d6VQEUgQtIAN4wvPTmlS8a3CxQAAnG49c0AW7HT7ia4USr5aZ6ueorqYvDWjf2nEb+WWYtz5aHYmPXNc5bTidiJJsSKuVK8kVq3V1NbWUb2snmyY4kxyDQBLrWnCC5l8m0txEpG3aMkCqujWr3FwrpAQitt6cAmrPh1tUv7nN07Bc5DkcD2rtrWw8oNCCW3NuAxjbxQBjx7pCYwrDcSMjjiuu8G6JH9rBiZMgZK5681iTQGO42iRRsOMgdT7123ge1D3qCWMFj0YHjFAHtXhOwigtVYZ38DA7HFdZtDIAR271k6BEiWqBTxnJPqa2aAK7wYTA5NCREqQTyBirFIRxxQByviGxzGy7sg9h1ryfUdHB1GWV4lkjzhlYc/nXrPiG9jjjmZ32hCeRXm8+rI28xyJubLbT1oAzJPDFtIFfygkY9B2qxZaVHpkcqorkLzz0xSxate3skUUpBiI+V8gYPvTtrz3Ekb3TeVt2Myt2oA5HX01G8urh9HRHXbyzD5QPT3puhW9w4ee7kSJtvzcECvQbWysLW0fyFdxt2n/HNczc6fJJOvl7ktVO4ueVPtigDCij8i5ECxlo8l8jv9TW6+lWCxLBPGsbONzMw5ww6Z/CmmCdJPkiAA4JZeTTPEc8620RMZLIRt8ts7wPbrQBn67oOnvaStEPLC4yB0OO1cedK1CIP9mBS0K78jOOvNel6Pa29zp6M7RvMF4XdkqfcVm3+6Lb9pACR8YDYx9fWgDnrKN5fsz70d8hfm5IHpXR2d3OjPFE+/byOwOO1ZMVjFcSKysUl3Fk2t1z14rd0yw+y5VwN+PkJ6N7+1AHbeH5xcRQyRKAmfnTqU9vpXpGjqVsY/Tace3tXkOhSSWVykxypyVIHRhXsekNG+nRNEfkcZWgCG5JSYnPB5q1C4Cse/WoLtc7DjBxUvKxhSQRQB4H+2Wc/DDTMdP7Yi/wDRE9eX/Ar/AJE64/6/X/8AQEr039sg/wDFsNMH/UYi/wDRE9eZfAr/AJE64/6/X/8AQEoA8Ku/+Pqb/fb+dfa9swO3v6ivii7/AOPqb/fb+dfZtlJkr044oA6PTyQRnrXY2b+ZBGx5A4Oa4vTmPmqOowOldfpJzEV64NAGmWBQgnipbSP94uAPxqLBIAOM+9XrNdnz9egoAw/G7smiFUxvkOwc44714B4lP2JflbDMDzX0H4wjWWMoegUj6V84/Ei9NnO8SDNwB3x8g9fqaAOB8QahJZK8ZQSTON2cfdz3/wDrVztteXUzqAQFzuYsOT+NT3sjSxhjukbdzkk1p6JZwTwhHAjdui9vrmgDTW03QpdxwsVyMEHk+/69Koayf7PtDDFbAvMCWlJ5IJ4/z7Vo38pEBgjkBRAC8gOFAHXkf54rm7jWYJLaRUR2YjAlfnn/AGR2oAyhbQx4F/L5ScsqgZdvwqpKkU6OIcQYXKrgkvyOPbufTiti6W3ubWGVUKyKu12bnP1qnbQpE7y5D7e49fQUAVrd209n8rDzEfKQDyvrXT+GXkmdG8rzAAUG4cA9zVrSfDUeqmO9eUQgdWJwPx9K9P8ADfhuwtrB3M6FUIbCDJ59+9AFXwlpCf2a7RhULtnPXp6Vpvoz+e5wB8u4kHOK2NPktQh+w4IwVA6/N9KvXEUot4vOYRvI21SowcUAecW2jzSLLNIN/wAxA9q7fwBaSwuJMDZnHfmtLSvDzQNlF3Ruc7+uT711mjWDxsm0LtHHAwc0AdvpEO21UH1zWrUNsu2JfoKmoAKCMiiigDgPHlo39mSrGp81ure1eV3OlmG2Z1iYyDHAOOPevftfhEtr83Iz09a5S40AXBLDIGOQ3SgDxwTzLaiSIMEjBBX0981v+FraSfTvOgX94fvMw6V2WpeFoXhS2woSReSvGD6mrOgWUmkQPDPECeinrmgDmTLeW8ckKxG4RlyyKME//WpYnZtL8ho2DEnarA5AHeuySwtxKblyFfHUVFeQ2upOAjKhxtAQ8Z//AFUAcMUNrDI0iMN65G4/N+H+e9Yy6U7xPcysqkNuQNJ0475rtdW8Pta25lKiW5I2xmPkL+dcVPHeuzR3EMywHglht/CgDGMs4nRVPksfm3x8AkDpTW1AuhOoI5TdksfvYpfEL7CgtIXSIMAwHPOPWqss0Eenv5qIjucEyHlh7UAaxt5JooZ7XA4BAQYIHuK6XT55BIkU+wtgb3POM9s1xAnlaK3XTrkxbgAeuU/z6V2Nlc28iR20jL5yYIPZ/cUAbDQsl0ssTfL0BPT8a9J8EzGXSQjMGKMcEe9ecW9/Am1ZvnjcbOn+ea9D8F2wtIZo1OYyQy/Q0AbdwmXA7Z6VA7biT71ZusgBh1wazmkClqAPB/2yG/4txpa/9RaM/wDkGavN/gV/yJ1x/wBfr/8AoCV3n7X84l8C6eoJONUj/wDRM1cH8Cv+ROuP+v1//QEoA8Ku/wDj6m/32/nX11pVwWKqTg9+a+Rbv/j6m/32/nX1forcjHLUAd1prAsvIwOtddpLAOedoNcPp74KnoQa6XTbrp3I6n0oA61SC2P1zWlbrlEH/AjWVbvvQEVsIv7ogHnbwaAON8d6gLSzd+sjkqg/r+FfMnjtmuvM2P5swPzMR2969t+Id2bi7nVXIjj+UHsK8cvYnnndImDAnknvQBwMMLpAyu+ISeWx1+lX7GaK0WOWZnKjAMYHzMM/y966gafFbgm4QSEEHyjyF9yf6Vyd1YXxvndoiGZtxc8ALngD2oA0r6/RbMrdRpErZMa7QAoxwOeprj5yomZQgMecArwc+taOswvdP+9kZgDwxy3txWro2gzwyN5w+baGjUjOSPegDO0fSzNcwxSh3gxhmPAGR1qafyIbu5hjETnJ2SNhc46+1b6WtzbyO1ywSNwMFRkH2A7nFV9YMMMZS0sGdehldBle/HpQBo6Lp1zKsLySxpaE7QWbIHHSu40a8Wz/ANBgAds5LMPvfQV55oEl+dQRZEdo1UEAjBx/KvRdEso7qSSbD+YpBzkjI9RQBLY3t7bXjmK0jRPMHy7OvtXX7/t8ib44wcdDn5fwqppCyy3TpAAyjO5guee1dBeWTQWKyyK29j2GOKAGWN41lb+QwWQgcbeM/hXV+H7pZrQnYMA9+tcOkv2cMDHvY4xnsPrXUeH5o7raSrKenJ4NAHerjaMdMcUtNiBEag9QKdQAUUUUAQ3ahoGBAP1rLU4BXr9elad5/q+Tjmse6mRIGYD5jwD2oApX04BL4Bx0xzWRJfz3sgESny0+8x9PQ1djbzXKqoJ75q1HapF5m9RhgfwzQBz0msW8hEcgby14PZs+v0pjNb2mbi0uVBHzssnBzWf4ja0tLeSMEKV7Z7+1ee6/qk8wh2kFIgCBnoexz3oA9Seb7bp5kE7gryFzyf8A61c7dS3TK8bqvl55DDjp/hWFpN3qEke1XWSJ1LYY4YZxyPb6VNf3t3awxNAzSb/kkjk5xxzQBmaykI01Gkt5BGZCpdc+lZ9holtcqXEjyRYDlpBjaRW5JPDeW3lOU3oDwDlfpxWAttewJJteaa3Y8pyBgdMGgC1dyRJal7ZVeROFYjp7e9c8l5MZM5ct24wR/hWpezyeY1tOI44TjeyHJ/E02ax89YjCPlDH54/4hQB0fg/V11M/ZbgH7RHzEcffA/rXunhc77Hpg8HBr5r0pHh1iFoBtkU78Yxn3r6N8H3BuLXzO7qGP1oA2b5j5LAdj2rmtRuxDuO4gjitvV5jFbz9M8Yrz/Wrh5FcMxbB79qAPH/2opzN4FsdzZI1OP8A9FS1zfwK/wCROuP+v1//AEBKv/tF3Ak8F2SdxqKH/wAhSVQ+BX/InXH/AF+v/wCgJQB4Vd/8fU3++386+otHmJZACOa+Xbv/AI+pv99v519EaPdYK5PHSgD0u0uRsBwMitezuf3gwe+K4+2uCIckjcRWzpE3nTjOdoHpzQB6Xo1xlFQ9SfzrpbmTZaysD0QgflXJ+H1PDjjauTx3rpL3cdOBB5K0AeJ+N5woIyAxyTxya88eeCxuFTf+/kO7PZB6n3rtviTKLGWV/lMh/wBWp7D1ryTdNdyFQvzcszMeufagDvdLktpzJCCzmQdx+tZ19Zi2LliJlIxt6gVQ06/hslZI8vM/yhyfu/59K62LT1u7EySR5cKArBiSfw7UAee6lZxSzqUiSR8ZbL4A+vtWjaXk1gYGPlsMDkocAeoB61r+KtMa2tFltokXby6j1HT3rlIjf6lcRs0pOzqjJjPcCgCprF09zeqouJmZm3Dd8uPbPpXWabLbPaNC6JKxAyerH6VmTaXBGY5Hi8ycHewJyqfQVfsbC2mvVFs4klbJKo+MH+6aANTTNHeWNnhKxRBicq2cj0rpLOSMtawWgkEhO0KRgn/61O0DR1uLXZKRBbjqisclvaul8P8Ah23ttV3sX3joWbOBQB03h7SodP0+ST/lrIdwwMZrW+yTSxKJAGyOMioU3x2xUsxYHIPcVs6SHkhAlyXH8WODQBzWpaEiRxn+Ink9Kt+HtPKTjBG0HORWxfRyzBkKkrVjSbXyIuV2k9s0AaNFFFABRRRQBFcp5keO4Oaxb63YjCED27Vv0zykyflHNAHL2dm0U+WbIbg8fyp+qrJsCQgHj5iR14rdNsvmklQc9KyLsSC9fzf9UBgcUAeP+JoZriMtIQJS5A549ifeuB1mZbSV4WBY4G7BwPcAGvoHUtIju4GkeJQAeCOD9eK8m8caDbIvnRedkv8AN/ETQBlaRdsLa2Id41ThccEA56/57VrWuqxalJcxycqGwCx5PrzXOokihFR/kA+ZDy2AKrwxXSXm4IQGHGwZDj1x60AbjARylrMfu9xZW55Hrj1+taGp34sLWKYyHcyY2MMD6EfjXPMZbN5PnwzqQULZwfWqGqa0NR0/yJdnnhvlkxjA96ANay1GHWJ5QttE8xX5lPysuPQ9xVuGMwuYcDG3IUn/AD+dcTYN/Z8yum5JGOPNBOD+Nb2p6rFeiKGGYJIBh1B+97qexoA6uw0+OIJOgR0PAYngH0969W+G8xMM0BIBGCB7d68n8LXsSwJbn94hG0hh3/xr1L4fRSR6k+4gr5fB9RQB0viEH7MXHOeD+deca++xJR0bHevTtcTNgcDo3avMvE0RJYY+h9KAPBPjzL5nhOz7/wCnLz/2zkqT4Ff8idcf9fr/APoCVV+OC7fCVqMf8v64/wC+JKtfAr/kTrj/AK/X/wDQEoA8Ku/+Pqb/AH2/nXtGhXm7Ga8Xu/8Aj6m/32/nXqvhsF5Qf5UAeoaexmgI5yORXZeGLfKKSTk9TXJeHoScDBHFei+GbYCEfL79aAO00WLbE/GOgrZ1L5LBh/dAqvokWFcMCTgHrTfFkph0lgvLSMEAoA8P+IsH9p3MrNuxGrbCpA+meORnt+teXXdv9mf9zu5Hy+5PrXsHiYCPbGh3E8EEZH4159q729kpaUDc55yc4oAxbezijvIZiW81sbkj6A+pFd9bXAtdOheA5lkb5mY9e2K8qN48+pGNOIyR8wOOK9K0e6j/ALHkjkkIt05Env2GaAN2azS5SN5wskbKRszkgnvWHe6LDCkrEtAyj5IwwH4k07TdZXySFfZFEP8AWue59BW5bTWGrxA3TCU7eWZsdD+lAHnaRSQBvN8zbMNpJB+b0rd8P6OkaLKzCFgcqSRyB1rtbODTWcyyNAYf74Yc4rDutStL28MdnG62qdkG0dfWgDodMBiQG4ISBTlAvJYfSt3Rdfgl1Hyo4yg25DSclvpXO6dtELpuBcjOWP3R2xSaDEbyQyPIWkVioUH3oA72N5p7j5uD9MAV1GmqVh2BsYHGO1YNrCyhCV+VgM1v6ciYA3HIoAlw6uCCcn3zVuI5QHuaaUBPABx781IowMCgBaKKKACiiigAooooAhmDhGKk5HTmqEod9x3HdjkelajDJFU5ICDKefrmgDCvbp1CoUXaODx1NcZ4iSOS1YTW5KHJbac5H0rtby03R8g4zx71zer2pYMmWyecEcY9KAPGdZsls79LiGTKE4RWODjr07mpbYbmAlJVeMnuM/5zmuk8V6SsmnlXh+aIMYzgnI61wkM8sccxVgN3Rc5Kn0oA17qF7y3EUUsc8yPiMj065J/GuR1MAyslu+052yNIcjr19a6rRzFEQRnzGGSyHJX1GK5fxPbs1wWtHQRytubnBFAFLXpZ0tYYmOATtGF4/OsnT5bi2lWN0Qoc5dTkj6Grc1/LLDb2koaQ8qSeSar3Cbpy/wBmbAA3KT6f0oA9G8MX6y7AgDTKMlRxketfQ/gWLzNPjuQPvAAH1FfJ/hi4ZLuOWPIkyNvuc19e+B9h8O2rIMAjkeh7j86ANLU13WjgeoNefeI7fCk4yf1Fej3a5gYHua4vXrfKuxAOKAPmD4/IV8K2RIAIvVH/AI5JS/Ar/kTrj/r9f/0BKu/tGxCPwjYkDrfr/wCi5KpfAr/kTrj/AK/X/wDQEoA8Ku/+Pqb/AH2/nXsPhKIuV6149d/8fU3++3869z8HW+VTPf8AlQB6foFttjXjBx616H4ah/drwMVyPh+AGNQPSu/0GICNc0AdRpSbUcZzwKqeLE3aep9D3rSsFAiJHrVfX0D6ZPnsM/SgDw7xPdJBbyhseZzsz3PrXkeuOsitKQZWzhhjOTXovi1mur2QDlQdqgdq4W7jELq3DvnnnigDmdPsvPlO9GVccj09q27/AFYwWKW0JKxRjJyOM+30q1Y7YpxLNjyurGqviC4sJblmBDsEBCBeAPU0AV9Dubi8uGIlwqjdh/uk12UN/HZaXJ5mxJCNpbGSfauGstQh02SGQKcSE5BGS2O/tUniHXg+6BVAabltp6Z4yKANLTdXlLyscuob7inHGeldBp17AYZtsbgOw3Dsvt715p54tZ9qSEkrknPoOa19GaSW5WdJyIQPmVs4bjt70Ae0aJfJNEsblQMeXHJj06ZrsfD9pHsbC4nXksq8GvnLTtcZbtoYDIsYbB59+1fSfhq4k/sKM5Xe6jcO/T1oA3dPlwqhTypwQeSPWti0cv8A6vOc9f8AGs/RrdTGJYgcHhg3OTWzbRhCGGQxPI9KAHhHjmypznqKt03Hz5xTqACiiigAooooAKKKKACkIyMGlooAozQk/KfrxWLfW7f3V25GT6+1dNIgcYP6VRubEyt1yCMGgDy/xEjYuDIMRk4GK8B195rbXntYQRHP8xcH+LPA+hr601Hw55kUgCeZu9+npXkfizwLI1/9xUA+YMR09aAPLbOSaFH2qxKfMrj2/nWHe31xLcPHLCoVQcEc47/nXuOk+EVsUDSxklhhTjt6muO8YeDnRxNZoUiJLfL/AFoA4GW3FzHHI5CyYBWRP/Zverc9pLGY5NxDEgtz196bqME1hcKrRFEb5QAOBn+lO0y58yZoLjDxkAKe4Pt7UAbvhfTTd6kskMYXB3Ef3j2/GvqbwICmj+X2UgfjjmvCfB+mm3mizndneWzXvng8D7BIy8ZYA/XFAGzcDMRrldcQbGPHPeuslGUNc1rifumHSgD5o/abjKeDrEnvqCf+i5KxfgV/yJ1x/wBfr/8AoCV0n7UylfBlgD0GooP/ACFLXN/Ar/kTrj/r9f8A9ASgDwq7/wCPqb/fb+dfQngyLmLivnu7/wCPqb/fb+dfR3gsKBDjdkDn079KAPWNBQKi9OnpXc6InyKQOTjmuM0NPkXAzxya7zRUxCn8hQB0NsAIzj1qnrx/4l7qOrcVehGEqjrQzAuenNAHhnirTxZSytgZkyR6qPT615rexu0rOMkfwjHU17N4zgW6LJkKQSQe4rybxHEBHNFGeV6ueKAOMvrl0MvzsCDtGD93vwKoQyAPl8MCvHqaNRLI6xsWKgcDrknrirdhoFzeSrI4ZAR0AyTigCk0Ukx8+U5KkZGewHpVOfdNL9oP8JPXrj0NereG/AwuFV5Yxu6qCPXtXUW3wzs5sKbVWyuD1AHPegDwe1t3vr1CA5Uggcd66BIJIIFiPy4OQi9Wr33TPh7pUbLHFYhUGM7Scsai1n4fWCTb1jbIBHyn5v8A61AHjOkx+W8pEQ6bfu84r2fwjq0P9lo0ku4AAFB1z0rNm8AW/lr5LXCADLKG61paD4LWCFo4JWALZxjBx6UAehaNfEqiouIm5966G13FsuMLng1l6JpgtUThj6k84raiPylSc+lAFkfWikUYHNLQAUUUUAFFFFABRRRQAUUUUAFFFFABVa6sre6ZTPGG28896s0UAZlxpEEucDgmsfUfDKyKyhA6N2xXV0UAeI+Lvh6t1FKVjIZgcjFeKPoVzperS2N3HhocMrlcbh619rSRpIMOoNcR4/8AAdt4gtPNtlVL2L5kbu3tQB5d4RZYlEMwYDGUf09q9y8JxGLRYt33mJY143p9jNxbSoVmiOMYwR7V7V4dfOmQoT8yKAaANJhkEVgauBjvya6CsDV8FsdupFAHzZ+1Wf8AijrH/sIp/wCipa5j4Ff8idcf9fr/APoCV0/7Vf8AyJ1hwP8AkIp/6KlrmPgV/wAidcf9fr/+gJQB4Vd/8fU3++386+ifBT58vnPFfO13/wAfU3++386958DzjbECcYOP1oA910E5VQMV32jD92oIxXnXhmQMiE+nrXpGhurRqce9AG8n3azPEOfsYI7HrWmvQVn66CdPkA6kcfWgDynxLN97B/3sfyrznXIDKFiRGkmk/u85P+Nd7qizvdCO3j3yscBepJ+nrXVeFPBYtpPtN0N9weeRkL7A+tAHkGhfDt7qVJ7+P94BhUHRB7+prv8ARfBUUZU+WSV68V6tDpcCKBsAH0qylrEn3VFAHL6X4chgRBHGFOPTrWva6ekO7I3PjsOgrXCgdBilwKAM2G1AcAJtA5zUwsIj98Bj1q5jFFAGZPpiuOAuexqKHRxGwORnPJzWxRQBXWMxDIx6Zp4H8ff3qWkAxQAicrz1p1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc14h8OR3V4NRtRtulGHUdJB6/UVpaIhWE59K06YkaozFeN3OKAH1z+tMoc5zn1roK5bXpAkjDuOKAPnH9qhgfClkAf8AmIIf/Ictc78Cv+ROuP8Ar9f/ANAStf8AadlD+GLIAk/6ehx/2zkrI+BX/InXH/X6/wD6AlAHhV3/AMfU3++3869f8FXeJlUkdq8gu/8Aj6m/32/nXdeEr7y7tEJ+bPGfSgD6c8KXGY154PY16foMwMa44z2rw/wdehgo3Egdq9c8P3BbaAeTigDvE5RfpWdq+51WNMlj2FaEX+qXHpUcMW0ln5c/pQBk6V4fhs53uJMPcOc7sfd9hW4AB0GKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAIB6jNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjHAP0zXEeLphFNJ9cj8q667l2NjvtP8AKvMPiDqKwKZXYBdoYnOKAPAP2iboTaLaR7iT9sVgD6bH5pPgV/yJ1x/1+v8A+gJXB/FbWzq9+dpzEkmF59jXefAr/kTrj/r9f/0BKAPCrv8A4+pv99v51q28zRSq6MVZTkEGsq7/AOPqb/fb+dXgcGgD274da+t6ow2LhPvpn9R7V714PvFkni5JA5PPSvinSr+exuo57aQxyqchhX0R8K/H1peZi1PFtdhdvmA/IxP8ulAH0zazZSMZ/hzVtG3KK5nS75ZQGSRWUcAg5zXQ2zlhntQBPRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFIByTQAtFRTSCJQFwD2HpTFnwuSQ30oAsUVB9pUdQfwqVJFfpn8aAHUUUUAFFV7i7jgHzZP0rltd8UXEEUn2ZFiAH3jyfw7UAWvE2qW+nI091MsUYVup68V8rfF3xvJq9wsFoWjtggAPdq7vxde3F4l1LczPNIqF8sfu9uBXgfiuTN5wc7VwKAOS1h96Dn+L+ley/Ar/kTrj/r9f/0BK8V1Jsxj/e/pXtXwK/5E64/6/X/9ASgDwq7/AOPqb/fb+dTfaU7Bvyraa3hYkmGMk8klRR9mg/54xf8AfAoGZMd6inJDfgBXQ+H/ABRaadv8+O4YMRnYB2+pqp9mg/54xf8AfAo+zQf88Yv++BQFj1Lw18bLLRnlwmqeWzbggRCP1evRNO/aj8PQxotzpmsOR94rDEP/AGpXzT9mg/54xf8AfAo+zQf88Yv++BQFj6rX9qzwZgbtI8Q59oYf/jtSD9qvwR30rxJ/4Dwf/Hq+UPs0H/PGL/vgUfZoP+eMX/fAoCx9X/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8ofZoP+eMX/fAo+zQf88Yv++BQFj6v/4ar8D/APQK8Sf+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8er5Q+zQf88Yv++BR9mg/wCeMX/fAoCx9X/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fKH2aD/AJ4xf98Cj7NB/wA8Yv8AvgUBY+r/APhqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6vlD7NB/wA8Yv8AvgUfZoP+eMX/AHwKAsfV/wDw1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fKH2aD/njF/wB8Cj7NB/zxi/74FAWPq/8A4ar8D/8AQK8Sf+A8H/x6j/hqvwP/ANArxJ/4Dwf/AB6vlD7NB/zxi/74FH2aD/njF/3wKAsfV/8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8ofZoP+eMX/fAo+zQf88Yv++BQFj6v/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6vlD7NB/zxi/74FH2aD/njF/3wKAsfV//AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fKH2aD/njF/3wKPs0H/PGL/vgUBY+r/+Gq/A/wD0CvEn/gPB/wDHqP8AhqvwP/0CvEn/AIDwf/Hq+UPs0H/PGL/vgUfZoP8AnjF/3wKAsfV//DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49Xyh9mg/wCeMX/fAo+zQf8APGL/AL4FAWPqO8/ah8FzbymmeItx6Zt4Rj/yNWZ/w0x4Y3AjT9eH0hi/+O183/ZoP+eMX/fAo+zQf88Yv++BQFj6eT9p/wAHbBu0zxDv74gh/wDjtXE/am8EKuDpfiT/AMB4P/j1fKv2aD/njF/3wKPs0H/PGL/vgUBY+rh+1X4IxzpXiT/wHg/+PUp/aq8D4/5BXiT/AMB4P/j1fKH2aD/njF/3wKPs0H/PGL/vgUBY+oLj9p/wZL93TPEQP/XvB/8AHa5bW/j94XvoysFjrYz/AH4Yh/KSvCPs0H/PGL/vgUfZoP8AnjF/3wKAselaj8WtCureZEtdTDSR7OYo8f8AodeZ6xrtve3DPEkwUgD5gM/zp32aD/njF/3wKPs0H/PGL/vgUBYwrqdZVAUEc55r3L4Ff8idcf8AX6//AKAleVfZoP8AnjF/3wK9h+DyKnhm5CKFH2tuAMfwJQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thirty-seven year old woman with a two week history of cough, dyspnea with exertion, fatigue, and fever. She developed respiratory failure and was hospitalized. Posteroanterior roentgenogram reveals bilateral patchy opacities and volume loss. An open lung biopsy confirmed an extensive&nbsp;COP pattern. There was complete resolution following&nbsp;glucocorticoid therapy without recurrence after&nbsp;glucocorticoids were discontinued.",
"    <div class=\"footnotes\">",
"     COP: cryptogenic organizing pneumonia.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8032=[""].join("\n");
var outline_f7_54_8032=null;
var title_f7_54_8033="Manidipine: International drug information";
var content_f7_54_8033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Manidipine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calslot (JP);",
"     </li>",
"     <li>",
"      Iperten (IT);",
"     </li>",
"     <li>",
"      Vascoman (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Manidipine Dihydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 10 mg once daily; may increase to 20 mg once daily after 1-2 weeks if needed",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, as dihydrochloride: 10 mg, 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10409 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8033=[""].join("\n");
var outline_f7_54_8033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304149\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979410\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979412\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979415\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979411\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821118\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979414\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10409\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10409|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8034="Patient information: Delirium (confusion) (The Basics)";
var content_f7_54_8034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16994\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/57/39824\">",
"         EEG (electroencephalogram)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/0/18434\">",
"         Patient information: EEG (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Delirium (confusion) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/delirium-confusion-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10514413\">",
"      <span class=\"h1\">",
"       What is delirium?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Delirium is a brain disorder that causes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble paying attention, or switching attention from 1 thing to another",
"       </li>",
"       <li>",
"        Memory, language, or other thinking problems",
"       </li>",
"       <li>",
"        Trouble knowing where you are, when it is, or who the people around you are",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with delirium are usually very sleepy or hard to wake up. But they can also be overly active or upset, or see or hear things that aren&rsquo;t really there.",
"     </p>",
"     <p>",
"      People with delirium don&rsquo;t usually have symptoms all the time. Their symptoms can come and go over the course of a day, and often get worse toward the end of the day. Delirium can last days to weeks, depending on what&rsquo;s causing it.",
"     </p>",
"     <p>",
"      There are other terms that might come up when doctors talk about delirium. Doctors sometimes use the term &ldquo;altered mental status&rdquo; for when a person&rsquo;s brain isn&rsquo;t working normally. The word &ldquo;confusion&rdquo; means a person isn&rsquo;t thinking clearly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10514428\">",
"      <span class=\"h1\">",
"       What causes delirium?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different kinds of conditions or situations can cause delirium. The most common causes of delirium are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Different medical conditions",
"       </li>",
"       <li>",
"        As a side effect of certain medicines",
"       </li>",
"       <li>",
"        From using illegal drugs",
"       </li>",
"       <li>",
"        Alcohol withdrawal &ndash; This is when people suddenly stop drinking after they have been drinking a lot of alcohol every day.",
"       </li>",
"       <li>",
"        Certain infections, seizures, or some types of strokes &ndash; Seizures are waves of abnormal electrical activity in the brain that can make people move or behave strangely. A stroke is when part of the brain is injured because it goes without blood for too long.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Delirium happens more often in people who:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Are in the hospital",
"       </li>",
"       <li>",
"        Just had surgery or are in pain",
"       </li>",
"       <li>",
"        Are older, have a lot of medical problems, or take a lot of medicines",
"       </li>",
"       <li>",
"        Have another brain disorder, such as dementia &ndash; Dementia is a disorder that causes memory problems and makes it hard to think clearly.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10514443\">",
"      <span class=\"h1\">",
"       Should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Many people who get delirium are already in a hospital. But if you are not in a hospital, you (or the person with you) should call the doctor or nurse if you have the symptoms listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10514458\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and ask questions to check your thinking and attention. He or she will do tests to find out what&rsquo;s causing your delirium. The tests will depend on your individual situation and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        A CT scan of your head &ndash; A CT scan is an imaging test that can create pictures of your brain.",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, your doctor will put a thin needle into your lower back and take out a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will send the spinal fluid to a lab for tests.",
"       </li>",
"       <li>",
"        An EEG (or &ldquo;electroencephalogram&rdquo;) &ndash; An EEG is a test that measures electrical activity in the brain and records brain wave patterns (",
"        <a class=\"graphic graphic_figure graphicRef55691 \" href=\"UTD.htm?38/57/39824\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10514473\">",
"      <span class=\"h1\">",
"       How is delirium treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors treat delirium by treating the cause of the delirium, if it can be treated. For example, if a medicine is causing delirium, the doctor will stop or change that medicine. If an infection is causing delirium, he or she will treat the infection.",
"     </p>",
"     <p>",
"      Doctors also treat delirium by helping a person&rsquo;s symptoms until the delirium gets better. Different ways doctors can do this include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Making the person&rsquo;s hospital room as quiet as possible, especially at night",
"       </li>",
"       <li>",
"        Giving the person medicine to help him or her sleep better at night",
"       </li>",
"       <li>",
"        Having the hospital staff remind the person where he or she is, and why he or she is in the hospital",
"       </li>",
"       <li>",
"        Giving the person medicine to help calm him or her down",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Also, it often helps people with delirium to have family and other familiar people around them in the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10514488\">",
"      <span class=\"h1\">",
"       Can delirium be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. Doctors try to lower the chances that patients in the hospital will get delirium by doing a few different things. These include making the patient&rsquo;s room quiet or helping the patient sleep well. If your family member is in the hospital, talk with his or her doctor or nurse about how to help prevent delirium.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10514503\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=see_link\">",
"       Patient information: EEG (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/54/8034?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16994 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8034=[""].join("\n");
var outline_f7_54_8034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514413\">",
"      What is delirium?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514428\">",
"      What causes delirium?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514443\">",
"      Should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514458\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514473\">",
"      How is delirium treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514488\">",
"      Can delirium be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10514503\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16994\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/57/39824\">",
"      EEG (electroencephalogram)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8035="MR normal fetal chest";
var content_f7_54_8035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Fetal MRI T2w of a normal chest at 32 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A), coronal (B) and sagittal (C) images demonstrate homogeneous high signal lung parenchyma with normal pulmonary vessels coursing through them. The heart is black due to flowing blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8035=[""].join("\n");
var outline_f7_54_8035=null;
var title_f7_54_8036="Sinecatechins: Patient drug information";
var content_f7_54_8036=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sinecatechins: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=see_link\">",
"     see \"Sinecatechins: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5195544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Veregen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat common warts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691858",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat genital warts.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sinecatechins or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain clothing or fabric.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not have sex when this drug is on your genital or anal skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Condoms or diaphragms may not work to stop pregnancy. Use some other kind of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put in the vagina or anus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid putting on healthy skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not cover with dressings.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not bathe, shower, or swim after putting on.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12002 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8036=[""].join("\n");
var outline_f7_54_8036=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5195544\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013187\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013186\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013191\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013192\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013194\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013189\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013190\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013195\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013196\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15923?source=related_link\">",
"      Sinecatechins: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8037="Prebiotics and probiotics for treatment of allergic disease";
var content_f7_54_8037=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Prebiotics and probiotics for treatment of allergic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Susan Prescott, MBBS, FRACP, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Christina West, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8037/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/54/8037/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11508576\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid increase in immune-mediated disorders such as allergic disease is strongly linked to reduced early microbial exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The gut microbiota represents the greatest microbial exposure by far and is central to the development of immune regulation. The specific composition of the gut microbiota may affect the risk of developing allergic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/3\">",
"     3",
"    </a>",
"    ]. This finding provided the foundation for intervention studies designed to modify gut microbial composition for the treatment of allergic disease. The effects of beneficial bacteria (probiotics) or resistant starches or fiber (prebiotics) that selectively stimulate a limited number of beneficial bacteria have been evaluated in allergy treatment studies.",
"   </p>",
"   <p>",
"    This review examines the evidence for prebiotics and probiotics in the treatment of allergic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. The evidence for prebiotics and probiotics in the prevention of allergic disease is presented separately. The definitions of prebiotics, probiotics, and synbiotics, proposed mechanisms of action, rationale for use in allergic disease, and side effects and safety are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31977?source=see_link\">",
"     \"Prebiotics and probiotics for prevention of allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11508604\">",
"    <span class=\"h1\">",
"     CLINICAL TREATMENT STUDIES USING PREBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials evaluating the effects of prebiotics for treatment of allergic disease are scarce and further studies are needed before any conclusions can be drawn.",
"   </p>",
"   <p>",
"    The effect of kestose, a fructo-fructooligosaccharide, was assessed in a trial that randomized 29 infants and children &lt;3 years of age with eczema to daily ingestion of kestose or maltose (placebo) for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/9\">",
"     9",
"    </a>",
"    ]. Median Scoring Atopic Dermatitis (SCORAD) scores were significantly lower at 6 and 12 weeks in the prebiotic group compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11508611\">",
"    <span class=\"h1\">",
"     CLINICAL TREATMENT STUDIES USING PROBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial meta-analyses suggest no benefit of oral probiotics in the treatment of eczema or asthma. One meta-analysis reported a beneficial effect of probiotics in the treatment of allergic rhinitis, but it was not conclusive and further studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938517\">",
"    <span class=\"h2\">",
"     Eczema",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of meta-analyses on using probiotics for eczema treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/6,10-12\">",
"     6,10-12",
"    </a>",
"    ]. Most have concluded that there is no consistent evidence that live oral probiotics are useful for the treatment of established eczema. Additional subgroup analyses according to evidence of allergen sensitization or eczema severity did not affect this conclusion. Subsequent trials have been consistent with these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/13\">",
"     13",
"    </a>",
"    ], although a small trial reported reduced SCORAD and improved quality of life measures in adults with eczema following 16 weeks treatment with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    salivarius strain compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are problems with the quality of some studies and with heterogeneity, which includes marked differences in probiotic preparations, study populations, and outcome measures, that hampers direct comparison of studies. LGG is the most extensively studied strain to date in the treatment of AD, with both positive and negative results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. Three other probiotic strains, L. fermentum VR1-003PCC, L. sakei KCTC 10755BP, and L. plantarum CJLP133, have reduced SCORAD scores significantly in more limited trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Preliminary data suggest that dead probiotic micro-organisms given orally or administered topically may be effective in the treatment of eczema, but further trials are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of probiotics in the treatment of allergic disease was first studied in infants with eczema, with or without associated food allergy. The initial study targeted infants with eczema and cow&rsquo;s milk allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/21\">",
"     21",
"    </a>",
"    ]. In that study, 27 infants were randomized to extensively hydrolyzed whey-formula (eHF) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    rhamnosus GG (LGG) for four weeks. The SCORAD score reductions were similar in the LGG and control groups.",
"   </p>",
"   <p>",
"    In another early study by the same group, infants fed eHF with added LGG or Bifidobacterium lactis (B. lactis) had a more rapid improvement of eczema compared with placebo (eHF alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, there was no effect of LGG administration on eczema in a study with a comparable design [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/16\">",
"     16",
"    </a>",
"    ]. Other groups have reported no benefit of LGG on SCORAD, medication requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], or subjective parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from a larger study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/19\">",
"     19",
"    </a>",
"    ] suggested that immunoglobulin E (IgE)-sensitized individuals might be more likely to benefit from probiotic treatment. In that study, there was a reduction in SCORAD scores in infants with IgE-associated eczema who had received LGG compared with placebo, even though there was no overall effect. These findings are consistent with another study that reported significant SCORAD improvement with probiotics in a subgroup of food sensitized children, while there was no overall effect in the whole study population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition of probiotics indicates that the microorganisms should be alive to exert their effects (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31977?source=see_link&amp;anchor=H3721155#H3721155\">",
"     \"Prebiotics and probiotics for prevention of allergic disease\", section on 'Definitions'",
"    </a>",
"    ). However, there is some evidence that dead probiotic microorganisms may also exert beneficial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/25\">",
"     25",
"    </a>",
"    ]. In one trial, 60 children (1 to 12 years of age) with eczema were randomized to heat-inactivated L. acidophilus L-92 or placebo for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/26\">",
"     26",
"    </a>",
"    ]. Both groups showed an improvement in eczema severity (as assessed by the Atopic Dermatitis Area and Severity Index), but the improvement was greater in the group assigned to L. acidophilus L-92. A much earlier study was also designed to compare the effect of viable or heat-inactivated LGG with a placebo in the treatment of eczema and cow&rsquo;s milk allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/28\">",
"     28",
"    </a>",
"    ]. However, this trial was terminated prematurely due to adverse effects (gastrointestinal symptoms) in the group of infants that received heat-inactivated LGG; therefore no firm conclusions can be drawn. Future research is needed to establish if inactivated micro-organisms are effective in the treatment of eczema.",
"   </p>",
"   <p>",
"    Most studies have used oral ingestion of probiotics, but there are limited studies on topical use. In one randomized trial, the topical application of a lysate of Vitreoscilla filiformis, a nonpathogenic gram-negative bacterium, led to a significant reduction in both SCORAD scores and cutaneous Staphylococcus aureus colonization, compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/27\">",
"     27",
"    </a>",
"    ]. These preliminary results need further validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5938524\">",
"    <span class=\"h2\">",
"     Allergic rhinitis and asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies using probiotics in the treatment of respiratory allergic disease have evaluated the effects of probiotics in the treatment of allergic rhinitis in adolescents and adults with conflicting results. A few studies report that certain probiotic strains such as Bifidobacterium longum (B. longum) BB536 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/29\">",
"     29",
"    </a>",
"    ], L. paracasei Lp33 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/30\">",
"     30",
"    </a>",
"    ], and L. acidophilus L92 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/31\">",
"     31",
"    </a>",
"    ] lessen symptoms of allergic rhinitis and improve quality of life, while there was no benefit of LGG [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/32\">",
"     32",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    casei strain Shirota [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is one published meta-analysis of probiotics in the treatment of allergic rhinitis and asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors identified marked heterogeneity between studies that makes direct comparison difficult. Probiotic treatment for allergic rhinitis was associated with lower symptoms scores and medication use in the 12 studies included in the meta-analysis. In addition, a subsequent trial in 63 children aged 7 to 12 years with confirmed house dust mite allergy and moderate to severe allergic rhinitis demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"     levocetirizine",
"    </a>",
"    plus a L. johnsonii strain was superior to levocetirizine alone for improving nasal peak expiratory flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/35\">",
"     35",
"    </a>",
"    ]. No benefit of probiotics was seen in the meta-analysis of four studies of probiotics in the treatment of asthma. This meta-analysis did not include a subsequently published study that showed a benefit of L. gasseri on objective airway measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic rhinitis often coexists with asthma; therefore a few studies have included subjects with both asthma and allergic rhinitis. One randomized trial of 187 preschool children with respiratory allergic disease (asthma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    allergic rhinitis) evaluated the effects of long-term consumption of fermented milk with the addition of a L. casei strain compared with nonfermented milk (placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/37\">",
"     37",
"    </a>",
"    ]. Episodes of rhinitis were fewer in the probiotic group during the 12 month intervention, but there was no reduction in episodes of asthma. However, it was not confirmed if the rhinitis episodes were of allergic or viral origin.",
"   </p>",
"   <p>",
"    Another study randomized 118 children aged 6 to 12 years with mild to moderate persistent asthma and persistent allergic rhinitis to daily intake of L. gasseri or placebo for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/36\">",
"     36",
"    </a>",
"    ]. Both groups reported a reduction in the clinical severity of asthma and allergic rhinitis following treatment, but the number of patients with an improved score was higher in the probiotic group. There was an increase in forced expiratory volume (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), forced vital capacity (FVC),",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC,",
"    </span>",
"    and post-bronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    following five weeks of treatment in children receiving probiotics compared with placebo, demonstrating an effect on objective airway measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11508618\">",
"    <span class=\"h1\">",
"     SYNBIOTICS FOR TREATMENT OF ALLERGIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies have used probiotics in combination with prebiotic oligosaccharides (synbiotics). In one study, 90 children one to three years of age with moderate to severe atopic dermatitis were randomized to daily intake of a synbiotic mixture with L. acidophilus DDS-1 and B. lactis UABLA-12 plus fructooligosaccharides (FOS) or placebo for eight weeks. Both groups had improved SCORAD scores, but the decrease was greater in the synbiotic compared with the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/38\">",
"     38",
"    </a>",
"    ]. In another trial, 90 infants &lt;7 months of age with atopic dermatitis were randomized to receive an extensively hydrolyzed whey formula with or without synbiotics (B. breve M-16V and a mixture of 90 percent galactooligosaccharides [GOS] and 10 percent FOS) for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/39\">",
"     39",
"    </a>",
"    ]. Overall there was no difference in SCORAD improvement between the two groups, but the SCORAD improvement was significantly greater in the synbiotic group than the placebo group in the subgroup of infants with IgE-associated eczema. This is consistent with a few probiotic treatment studies that reported no overall effect, but found a benefit in infants and children with evidence of IgE-sensitization to foods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study has evaluated if synbiotics are superior to prebiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/40\">",
"     40",
"    </a>",
"    ]. In this trial, 60 children aged 2 to 14 years with moderate to severe eczema were randomized to synbiotics (L. salivarius plus fructooligosaccharides) or fructooligosaccharides alone for eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/40\">",
"     40",
"    </a>",
"    ]. SCORAD scores following treatment were significantly lower in the synbiotic group compared with prebiotic therapy, in conjunction with a reduction in eosinophilic cationic protein (ECP) levels and frequency of medication use.",
"   </p>",
"   <p>",
"    Synbiotics in the treatment of asthma were evaluated in a trial that randomized 29 adults with asthma and house dust mite allergy to synbiotics (B. breve M-16V and a mixture of 90 percent GOS and 10 percent FOS) or placebo for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8037/abstract/41\">",
"     41",
"    </a>",
"    ]. Peak expiratory flow and systemic T helper type 2 (Th2) cytokines were reduced in the synbiotic group compared with placebo, but there was no effect on bronchial inflammation. These results are preliminary and need confirmation in other clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11508632\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prebiotics are nondigestible carbohydrates that stimulate the growth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      activity of beneficial colonic bacteria. Probiotics are live microorganisms that benefit the host. Synbiotics are a combination of prebiotics and probiotics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31977?source=see_link&amp;anchor=H3721155#H3721155\">",
"       \"Prebiotics and probiotics for prevention of allergic disease\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is evidence from animal models and in vitro studies that gut microbiota modulate immune programming, promote oral tolerance, and are important inhibiting the development of the allergic phenotype. However, the therapeutic effect of prebiotics or probiotics may be reduced once colonization and the allergic phenotype are established compared with treatment at younger ages when there is greater plasticity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31977?source=see_link&amp;anchor=H4478747#H4478747\">",
"       \"Prebiotics and probiotics for prevention of allergic disease\", section on 'Rationale for prebiotics and probiotics in allergic disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31977?source=see_link&amp;anchor=H4478782#H4478782\">",
"       \"Prebiotics and probiotics for prevention of allergic disease\", section on 'Proposed mechanisms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are several limitations that have hampered direct comparison of probiotic studies, including the quality of some studies and significant heterogeneity, such as marked differences in probiotic preparations, study populations, and outcome measures. (See",
"      <a class=\"local\" href=\"#H11508611\">",
"       'Clinical treatment studies using probiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no definitive evidence that prebiotics, probiotics, or synbiotics have efficacy in the treatment of any allergic conditions. Initial meta-analyses suggest no benefit of probiotics in the treatment of eczema or asthma. One meta-analysis reported a beneficial effect of probiotics in the treatment of allergic rhinitis and studies evaluating prebiotics and synbiotics in the treatment of allergic disease show some promise. However, further studies are needed before any definitive conclusions can be drawn. (See",
"      <a class=\"local\" href=\"#H11508604\">",
"       'Clinical treatment studies using prebiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11508611\">",
"       'Clinical treatment studies using probiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11508618\">",
"       'Synbiotics for treatment of allergic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/1\">",
"      Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/2\">",
"      Wold AE. The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Allergy 1998; 53:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/3\">",
"      Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007; 62:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/4\">",
"      Johannsen H, Prescott SL. Practical prebiotics, probiotics and synbiotics for allergists: how useful are they? Clin Exp Allergy 2009; 39:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/5\">",
"      Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010; 160:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/6\">",
"      Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr 2010; 22:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/7\">",
"      Thomas DW, Greer FR, American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/8\">",
"      Yao TC, Chang CJ, Hsu YH, Huang JL. Probiotics for allergic diseases: realities and myths. Pediatr Allergy Immunol 2010; 21:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/9\">",
"      Shibata R, Kimura M, Takahashi H, et al. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. Clin Exp Allergy 2009; 39:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/10\">",
"      Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2008; :CD006135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/11\">",
"      Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008; 121:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/12\">",
"      Michail SK, Stolfi A, Johnson T, Onady GM. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2008; 101:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/13\">",
"      Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy 2012; 42:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/14\">",
"      Drago L, Iemoli E, Rodighiero V, et al. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol 2011; 24:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/15\">",
"      Isolauri E, Arvola T, S&uuml;tas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/16\">",
"      Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy 2006; 36:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/17\">",
"      F&ouml;lster-Holst R, M&uuml;ller F, Schnopp N, et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/18\">",
"      Gr&uuml;ber C, Wendt M, Sulser C, et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/19\">",
"      Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/20\">",
"      Sistek D, Kelly R, Wickens K, et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 2006; 36:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/21\">",
"      Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/22\">",
"      Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005; 90:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/23\">",
"      Woo SI, Kim JY, Lee YJ, et al. Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome. Ann Allergy Asthma Immunol 2010; 104:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/24\">",
"      Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol 2012; 23:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/25\">",
"      Adams CA. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 2010; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/26\">",
"      Torii S, Torii A, Itoh K, et al. Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children. Int Arch Allergy Immunol 2011; 154:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/27\">",
"      Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/28\">",
"      Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003; 36:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/29\">",
"      Xiao JZ, Kondo S, Yanagisawa N, et al. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin Exp Allergy 2006; 36:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/30\">",
"      Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 2004; 15:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/31\">",
"      Ishida Y, Nakamura F, Kanzato H, et al. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. J Dairy Sci 2005; 88:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/32\">",
"      Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy 2002; 57:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/33\">",
"      Tamura M, Shikina T, Morihana T, et al. Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial. Int Arch Allergy Immunol 2007; 143:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/34\">",
"      Vliagoftis H, Kouranos VD, Betsi GI, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol 2008; 101:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/35\">",
"      Lue KH, Sun HL, Lu KH, et al. A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years. Int J Pediatr Otorhinolaryngol 2012; 76:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/36\">",
"      Chen YS, Jan RL, Lin YL, et al. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatr Pulmonol 2010; 45:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/37\">",
"      Giovannini M, Agostoni C, Riva E, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res 2007; 62:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/38\">",
"      Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol 2010; 11:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/39\">",
"      van der Aa LB, Heymans HS, van Aalderen WM, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. Clin Exp Allergy 2010; 40:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/40\">",
"      Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol 2012; 166:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8037/abstract/41\">",
"      van de Pol MA, Lutter R, Smids BS, et al. Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics. Allergy 2011; 66:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13582 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.150-5961A29943-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8037=[""].join("\n");
var outline_f7_54_8037=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11508632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11508576\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11508604\">",
"      CLINICAL TREATMENT STUDIES USING PREBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11508611\">",
"      CLINICAL TREATMENT STUDIES USING PROBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938517\">",
"      Eczema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5938524\">",
"      Allergic rhinitis and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11508618\">",
"      SYNBIOTICS FOR TREATMENT OF ALLERGIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11508632\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31977?source=related_link\">",
"      Prebiotics and probiotics for prevention of allergic disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8038="Topical cocaine: Drug information";
var content_f7_54_8038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Topical cocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/41/35476?source=see_link\">",
"    see \"Topical cocaine: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/38/32355?source=see_link\">",
"    see \"Topical cocaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical application (ear, nose, throat, bronchoscopy): Dosage depends on the area to be anesthetized, tissue vascularity, technique of anesthesia, and individual patient tolerance; the lowest dose necessary to produce adequate anesthesia should be used; concentrations of 1% to 10% may be used, with 4% being the most frequently used concentration (maximum total dose: 3 mg/kg",
"     <b>",
"      or",
"     </b>",
"     200 mg) (Liao, 1999). Lasts for 30 minutes or longer depending on concentration and vascularity of anesthetized tissue. Use reduced dosages for children, elderly, or debilitated patients.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as hydrochloride: USP: 100% (5 g, 25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as hydrochloride: 4% (4 mL, 10 mL); 10% (4 mL, 10 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F154125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Use only on mucous membranes of the oral, laryngeal, and nasal cavities. Do not use on extensive areas of broken skin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical anesthesia (and vasoconstriction) for mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CNS stimulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Loss of taste perception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Loss of smell",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Heart rate decreased with low doses, tachycardia with moderate doses, hypertension, cardiomyopathy, cardiac arrhythmia, myocarditis, QRS prolongation, Raynaud's phenomenon, cerebral vasculitis, thrombosis, fibrillation (atrial), flutter (atrial), sinus bradycardia, CHF, pulmonary hypertension, sinus tachycardia, tachycardia (supraventricular), arrhythmia (ventricular), vasoconstriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, nervousness, restlessness, euphoria, excitation, headache, psychosis, hallucinations, agitation, seizure, slurred speech, hyperthermia, dystonic reactions, cerebral vascular accident, vasculitis, clonic-tonic reactions, paranoia, sympathetic storm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin infarction, pruritus, madarosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, anorexia, colonic ischemia, spontaneous bowel perforation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Priapism, uterine rupture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea (extrapyramidal), paresthesia, tremor, fasciculations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Mydriasis (peak effect at 45 minutes; may last up to 12 hours), sloughing of the corneal epithelium, ulceration of the cornea, iritis, chemosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Myoglobinuria, necrotizing vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Tachypnea, nasal mucosa damage (when snorting), hyposmia, bronchiolitis obliterans organizing pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: &ldquo;Washed-out&rdquo; syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cocaine or any component of the topical solution; ophthalmologic anesthesia (causing sloughing of the corneal epithelium)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cocaine abuse: Use with caution in patients with a history of cocaine abuse. In patients being treated for cardiovascular complication of cocaine abuse, avoid beta-blockers for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only. Limit to office and surgical procedures only. Use caution in patients with severely traumatized mucosa and sepsis in the region of the proposed application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (strong), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Cocaine may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Cocaine may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13862039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this product. Cocaine rapidly crosses the placenta in concentrations equal to those in the mother. Adverse events occur in the fetus (eg, congenital malformations, growth restriction), infant (neonatal abstinence syndrome), and mother (eg, preterm labor, placental abruption) following maternal abuse (Fajemirokun-Odudeyi, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F154098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cocaine rapidly enters breast milk. Irritability, hypertension, tachypnea, tachycardia, and tremors have been reported in nursing infants (Chasnoff, 1987).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cocaine HCl External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (4 mL): $136.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (4 mL): $224.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F154086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F154090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 100-500 ng/mL (SI: 330 nmol/L); Toxic: &gt;1000 ng/mL (SI: &gt;3300 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Kokain (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction; interferes with the uptake of norepinephrine by adrenergic nerve terminals producing vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following topical administration to mucosa:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: &sim;1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: &sim;5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dose dependent): &ge;30 minutes; cocaine metabolites may appear in urine of neonates up to 5 days after birth due to maternal cocaine use shortly before birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed through mucous membranes (~35% absorbed when applied intranasally with cottonoid pledget) (Liao, 1999); limited by drug-induced vasoconstriction (eg, topical epinephrine); enhanced by inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; major metabolites are ecgonine methyl ester and benzoyl ecgonine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 75 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (&lt;10% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beckman KJ, Parker RB, Hariman RJ, et al, &ldquo;Hemodynamic and Electrophysiological Actions of Cocaine. Effects of Sodium Bicarbonate as an Antidote in Dogs,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1991, 83(5):1799-807.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/1850669/pubmed\" id=\"1850669\" target=\"_blank\">",
"        1850669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogan WC 3d, Lange RA, Glamann DB, et al, &ldquo;Recurrent Coronary Vasoconstriction Caused by Intranasal Cocaine; Possible Role for Metabolites,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1992, 116(7):556-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/1543310/pubmed\" id=\"1543310\" target=\"_blank\">",
"        1543310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chasnoff IJ, Lewis DE, and Squires L, &ldquo;Cocaine Intoxication in Breast-Fed Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1987, 80(6):836-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/3684393/pubmed\" id=\"3684393\" target=\"_blank\">",
"        3684393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fajemirokun-Odudeyi O and Lindow SW, \"Obstetric Implications of Cocaine Use in Pregnancy: A Literature Review,\"",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2004, 112(1):2-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/14687731/pubmed\" id=\"14687731\" target=\"_blank\">",
"        14687731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fritsma GA, Leikin JB, Maturen AJ, et al, &ldquo;Detection of Anticardiolipin Antibody in Patients With Cocaine Abuse,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1991, 9(Suppl 1):37-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greenglass EJ, &ldquo;The Adverse Effects of Cocaine on the Developing Human,&rdquo; Yaffe SJ and Arana JV, eds,",
"      <i>",
"       Pediatric Pharmacology: Therapeutic Principles in Practice",
"      </i>",
"      , 2nd ed, Philadelphia, PA: WB Saunders Co, 1992, 598-604.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill GE, Ogunnaike BO, and Johnson ER, &ldquo;General Anaesthesia for the Cocaine Abusing Patient. Is it Safe?&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2006, 97(5):654-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/16914461/pubmed\" id=\"16914461\" target=\"_blank\">",
"        16914461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander J, Hoffman RS, Shih RD, et al, &ldquo;Coronary Artery Disease in Patients With Cocaine Associated Myocardial Infarction,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2:456.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander JE, Burstein JL, Hoffman RS, et al, &ldquo;Cocaine-Associated Myocardial Infarction,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1995, 107(5):1237-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/7750312/pubmed\" id=\"7750312\" target=\"_blank\">",
"        7750312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kain ZN, Kain TS, and Scarpelli EM, &ldquo;Cocaine Exposure in Utero: Perinatal Development and Neonatal Manifestations - Review,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1992, 30:607-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kloner RA and Rezkalla SH, &ldquo;Cocaine and the Heart,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(6):487-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/12571254/pubmed\" id=\"12571254\" target=\"_blank\">",
"        12571254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liao BS, Hilsinger RL Jr, Rasgon BM, et al, \"A Preliminary Study of Cocaine Absorption From the Nasal Mucosa,\"",
"      <i>",
"       Laryngoscope",
"      </i>",
"      , 1999, 109(1):98-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/9917048/pubmed\" id=\"9917048\" target=\"_blank\">",
"        9917048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange RA and Hillis LD, &ldquo;Cardiovascular Complications of Cocaine Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(5):351-8; published erratum appears in",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(19):1432.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicholson KE and Rogers JE, &ldquo;Cocaine and Adrenaline Paste: A Fatal Combination?&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1995, 311(6999):250-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richards CF, Clark RF, Holbrook T, et al, &ldquo;The Effect of Cocaine and Amphetamines on Vital Signs in Trauma Patients,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(1):59-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/7782627/pubmed\" id=\"7782627\" target=\"_blank\">",
"        7782627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shannon RP, Manders WT, and Shen YT, &ldquo;Role of Blood Doping in the Coronary Vasoconstrictor Response to Cocaine,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 92(1):96-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/7788924/pubmed\" id=\"7788924\" target=\"_blank\">",
"        7788924",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd K, Hollander JE, Heilpern K, et al, &ldquo;Prevalence of the Use of Cocaine in Patients With Chest Pain,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2:344.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trabulsy ME, &ldquo;Cocaine Washed Out Syndrome in a Patient With Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(5):538-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8038/abstract-text/7662059/pubmed\" id=\"7662059\" target=\"_blank\">",
"        7662059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10133 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8038=[""].join("\n");
var outline_f7_54_8038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154123\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154110\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154111\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154089\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154073\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154125\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154092\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154091\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154121\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154095\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154077\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154119\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154082\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154084\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13862039\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154113\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154098\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323076\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154086\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154090\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038586\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154076\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154094\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10133|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/38/32355?source=related_link\">",
"      Topical cocaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/41/35476?source=related_link\">",
"      Topical cocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8039="Clinical manifestations and diagnosis of vaginal atrophy";
var content_f7_54_8039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of vaginal atrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Gloria Bachmann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Richard J Santen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8039/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/54/8039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal atrophy (also referred to as vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis) is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to loss of estrogen. It typically occurs in menopausal women, but can occur in women of any age who experience a decrease in estrogenic stimulation of the urogenital tissues. In premenopausal women, hypoestrogenic states include the postpartum period, lactation, and during administration of antiestrogenic drugs.",
"   </p>",
"   <p>",
"    Up to 70 percent of women with symptoms of vaginal atrophy do not discuss their condition with a health care provider [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/1\">",
"     1",
"    </a>",
"    ]. Some because they believe their symptoms are an expected and necessary part of the aging process [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/2\">",
"     2",
"    </a>",
"    ]. Cultural, religious, and societal beliefs may also play a role in making women feel uncomfortable discussing concerns related to the genitourinary system. In addition, many women are not aware of treatment options. Rather than seeking treatment, women commonly make lifestyle changes to deal with their symptoms. As an example, they may stop sexual activity due to dyspareunia caused by vaginal dryness.",
"   </p>",
"   <p>",
"    Clinical manifestations and diagnosis of vaginal atrophy are reviewed here. Treatment of symptomatic vaginal atrophy, as well as use of estrogen therapy for other menopausal symptoms, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=see_link\">",
"     \"Preparations for postmenopausal hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urogenital atrophy results from a decline in the serum estrogen concentration. In premenopausal women, estradiol is the predominant form of circulating estrogen. Serum estradiol concentrations in premenopausal women fluctuate during the menstrual cycle (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ), as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early follicular phase - 40 to 60",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Ovulation - 200 to 600",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Early luteal phase - 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Mid-luteal phase - 200",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Onset of menses - 30 to 50",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Estrogen stimulation is responsible for maintaining a well-epithelialized vaginal vault during the reproductive years. Estrogen acts on its receptors in the vagina, vulva, urethra, and trigone of the bladder to [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintain the collagen content of epithelium, which affects its thickness and elasticity",
"     </li>",
"     <li>",
"      Maintain acid mucopolysaccharides and hyaluronic acid, which keeps epithelial surfaces moist",
"     </li>",
"     <li>",
"      Maintain optimal genital blood flow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the nonkeratinized stratified squamous epithelium of the vagina in response to estrogen is thick, rugated, and rich in glycogen. Glycogen from sloughed cells is the substrate for D&ouml;derlein's lactobacilli, which convert glucose into lactic acid, thereby creating an acidic vaginal environment (the pH of an estrogenized vagina ranges from 3.5 to 5.0). The acidity of the vagina helps maintain the normal vaginal flora and protect the urogenital area from vaginal and urinary tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Menopause leads to a dramatic reduction in estrogen production, with an approximately 95 percent decline in estradiol concentration from the premenopausal to postmenopausal state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/4\">",
"     4",
"    </a>",
"    ]. After menopause, estradiol concentrations plateau at levels averaging 5",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/5\">",
"     5",
"    </a>",
"    ]. (It should be noted that most estradiol assays are not sufficiently sensitive to detect postmenopausal estradiol levels accurately).",
"   </p>",
"   <p>",
"    This drop in estrogen concentration, exacerbated by the normal aging process, is responsible for many of the adverse changes seen with vaginal atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These changes usually develop gradually, over a period of years, and, for many women, persist unless they are treated. Hypoestrogenic changes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thinning of the top layer of superficial epithelial cells, which may be entirely lacking in women with severe atrophy",
"     </li>",
"     <li>",
"      Loss of elasticity of the vaginal epithelium",
"     </li>",
"     <li>",
"      Increased subepithelial connective tissue",
"     </li>",
"     <li>",
"      Loss of rugae",
"     </li>",
"     <li>",
"      Shortening and narrowing of the vaginal canal, with loss of distensibility",
"     </li>",
"     <li>",
"      Reduction in vaginal secretions from 3 to 4",
"      <span class=\"nowrap\">",
"       g/four",
"      </span>",
"      hours to 1.7",
"      <span class=\"nowrap\">",
"       g/four",
"      </span>",
"      hours",
"     </li>",
"     <li>",
"      Increase in vaginal pH to &ge;5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thinning of the vaginal epithelium makes it more susceptible to trauma, leading to bleeding, petechiae, and ulceration with any pressure, including the performing of a Papanicolaou smear (",
"    <a class=\"graphic graphic_figure graphicRef71191 \" href=\"UTD.htm?21/2/21537\">",
"     figure 2",
"    </a>",
"    ). Thinning also exposes the underlying connective tissue, which is more vulnerable to inflammation or infection.",
"   </p>",
"   <p>",
"    The low glycogen content of the thinned epithelium leads to a reduction in lactic acid production by lactobacilli, resulting in an increase in vaginal pH. These changes in the vaginal environment encourage the overgrowth of nonacidophilic coliforms and the disappearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    species, thereby predisposing affected women to infection by skin and rectal flora (eg, streptococci, staphylococci, coliforms, diphtheroids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/4\">",
"     4",
"    </a>",
"    ]), as well as Candida species, bacterial vaginosis, and Trichomonas species. The shifting flora and resulting inflammatory changes were the source of the older term for this condition, atrophic vaginitis.",
"   </p>",
"   <p>",
"    Urinary tract structures are derived from the same embryologic origin as the genital tract and also contain estrogen receptors. Thus, the bladder, urethra, pelvic floor musculature, and endopelvic fascia are affected by a hypoestrogenic state. Possible consequences of atrophy of the urinary tract include urethral discomfort, urinary frequency, hematuria, dysuria, and an increased frequency of urinary tract infection.",
"   </p>",
"   <p>",
"    Menopause is a risk factor for both pelvic organ prolapse and stress urinary incontinence. While it might seem intuitive that estrogen therapy would be useful in the treatment of these problems, studies have shown that estrogen therapy does ameliorate stress incontinence and may actually change the supporting structures around the bladder such that incontinence is exacerbated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of urinary incontinence\", section on 'Estrogen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719871\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of vaginal dryness by age group was best illustrated in a longitudinal study in which the symptom was reported by 3 percent of women of reproductive age, 4 percent of women in early menopausal transition, 21 percent of women in the later years of the menopausal transition, and 47 percent of women three years postmenopause (",
"    <a class=\"graphic graphic_figure graphicRef82933 \" href=\"UTD.htm?34/59/35760\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Similarly, an international survey of over 4000 menopausal women reported that 39 percent had experienced menopause-related vaginal discomfort; 52 percent of those with vaginal discomfort reported that their quality of life had been affected by this symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal atrophy occurs primarily in women who are peri- or postmenopausal. Conditions or medications that induce a transient or chronic hypoestrogenic state can also cause atrophic vaginal changes. Etiologies of vaginal atrophy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Natural menopause",
"     </li>",
"     <li>",
"      Bilateral oophorectomy",
"     </li>",
"     <li>",
"      Spontaneous premature ovarian failure",
"     </li>",
"     <li>",
"      Ovarian failure due to radiation therapy, chemotherapy, or an adverse consequence of uterine artery embolization; these may be temporary or permanent",
"     </li>",
"     <li>",
"      Premenopausal use of medications with anti-estrogenic effects, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , gonadotropin-releasing hormone agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"       nafarelin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      ) or antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30099?source=see_link\">",
"       ganirelix",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Postpartum reduction in estrogen production, particularly during lactation",
"     </li>",
"     <li>",
"      Prolactin elevation due to hypothalamic-pituitary disorders with secondary reduction of estrogen secretion by the ovary",
"     </li>",
"     <li>",
"      Amenorrhea in the setting of severe systemic lupus erythematosus or rheumatoid arthritis (due to hypothalamic hypogonadism or primary ovarian insufficiency) combined with glucocorticoid therapy. The combined suppression of ovarian and adrenal activity (loss of adrenal androstenedione reduces estradiol synthesized through extraovarian aromatization) results in extremely low estradiol levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors other than low estrogen levels can modulate the degree of atrophy. For example, cigarette smoking, cessation of coital activity, vaginal nulliparity, and vaginal surgery may intensify vaginal atrophy symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/2\">",
"     2",
"    </a>",
"    ]. Cigarette smoking causes relative estrogen deficiency and may reduce vaginal perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/3\">",
"     3",
"    </a>",
"    ]. Abstinence from sexual activity exacerbates atrophic changes, whereas sexual activity helps preserve the vaginal epithelium, presumably by increasing blood flow and tissue elasticity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of urogenital atrophy include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal dryness",
"     </li>",
"     <li>",
"      Vaginal burning or irritation",
"     </li>",
"     <li>",
"      Decreased vaginal lubrication during sexual activity",
"     </li>",
"     <li>",
"      Dyspareunia, including vulvar or vaginal pain (at the introitus or within the vagina)",
"     </li>",
"     <li>",
"      Vulvar or vaginal bleeding (eg, postcoital bleeding, fissures)",
"     </li>",
"     <li>",
"      Vaginal discharge (leukorrhea or yellow and malodorous)",
"     </li>",
"     <li>",
"      Pelvic pressure or a vaginal bulge",
"     </li>",
"     <li>",
"      Urinary tract symptoms (eg, urinary frequency, dysuria, urethral discomfort, hematuria)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of vaginal atrophy are usually progressive and worsen as time passes and hypoestrogenism continues. Early in the menopause transition, women may notice a slight decrease in vaginal lubrication upon sexual arousal, which is often one of the first signs of estrogen insufficiency. As the hypoestrogenic state becomes chronic, additional symptoms may be reported by the woman, including a sensation of vaginal dryness during daily activities, not necessarily during sexual activity (the most common symptom), and other symptoms may develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of urogenital atrophy is clinical, based upon characteristic symptoms and findings on history and physical examination. Laboratory tests to confirm hypoestrogenic findings are available, but such testing is typically not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are peri- or postmenopausal or who have other etiologies of hypoestrogenism should be asked about symptoms of urogenital atrophy during routine clinical visits. As noted above, many women with these symptoms do not bring them to the attention of a clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Menstrual and medication history should be taken to assess menopausal status and evaluate for etiologies of low estrogen other than menopause. The clinician should ask about response to any previous interventions. A complete review of systems should be performed, as urogenital symptoms may be due to etiologies other than loss of estrogen. The clinician should elicit symptoms that may be associated with infection or inflammatory conditions, as well as use of products that may be irritants or result in allergic reactions (eg, perfumes, powders, panty liners, soaps, deodorants, spermicides, lubricants, tight clothing) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/10\">",
"     10",
"    </a>",
"    ]. This should also include a history of pelvic radiation. A pertinent sexual history should be taken to evaluate whether the symptoms are associated with sexual activity. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Quality of life issues should also be assessed; these include degree of discomfort, behavioral responses to symptoms, as well as the impact of symptoms on daily activities, sexual activity, and partner relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/11\">",
"     11",
"    </a>",
"    ]. The clinician should ask about the woman's therapeutic goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pelvic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external genitalia may show scarce pubic hair, diminished elasticity and turgor of the vulvar skin, introital narrowing or decreased moisture, and fusion or resorption of the labia minora [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In severe cases, the labia majora may be fused (",
"    <a class=\"graphic graphic_picture graphicRef54086 \" href=\"UTD.htm?10/0/10245\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/2\">",
"     2",
"    </a>",
"    ]. Loss of the labial fat pad gives the labia majora a pendulous appearance and makes the labia minora less distinct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    makes the clitoris appear more protuberant. A urethral caruncle may be present and appear as proliferative red tissue at the opening of the urethra. Urethral prolapse or polyps may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1380?source=see_link\">",
"     \"Urethral caruncle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with severe atrophic changes, exercise caution when performing the speculum and bimanual examinations, as even gentle contact can cause pain and bleeding. Assess for introital stenosis using a gloved finger before attempting insertion of the speculum. A lubricated Pederson speculum is more comfortable for the patient than a Graves speculum (",
"    <a class=\"graphic graphic_picture graphicRef78911 \" href=\"UTD.htm?0/53/849\">",
"     picture 2",
"    </a>",
"    ). A narrow Pederson speculum or a pediatric speculum may be necessary for examining some patients.",
"   </p>",
"   <p>",
"    Classic vaginal findings of atrophy include a pale, dry vaginal epithelium that is smooth and shiny with loss of most rugation. If inflammation is present, there may be patchy erythema, petechiae, and blood vessels visible through the thinned epithelium, friability, bleeding, and discharge. The vagina may be shortened, narrowed, and poorly distensible. The cervix may become flush with the vault as the vaginal fornices become obliterated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests are usually not necessary, other than for exclusion of other etiologies under consideration. However, a clinical diagnosis of estrogen deficiency can be supported by laboratory studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal pH - The most clinically helpful laboratory test is pH of the vaginal vault secretions. This can be measured in the office with pH paper. The pH of an estrogenized vagina ranges from 3.5 to 5.0. Vaginal pH may reach levels of 5.5 to 6.8 or higher in postmenopausal women, especially those who are not on estrogen therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/14\">",
"       14",
"      </a>",
"      ]. Thus, a pH of &ge;5 of the vaginal vault in the absence of other causes, such as infection or semen in the vaginal vault after recent intercourse, can be considered an indicator of vaginal atrophy due to estrogen deficiency.",
"     </li>",
"     <li>",
"      Maturation index - The maturation index can be used to quantify the proportions of cell types of the vaginal epithelium [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/15\">",
"       15",
"      </a>",
"      ]. It is determined from cytologic examination of a wet preparation of surface cells from the upper one-third of the vagina. The maturation index is the proportion of parabasal, intermediate, and superficial cells in each 100 cells counted on a smear. In premenopausal women with adequate estrogen levels, intermediate and superficial cells predominate. The maturation index for these women is typically 40 to 70 intermediate cells, 30 to 60 superficial cells, and 0 parabasal cells. In women with vaginal atrophy, an increase in parabasal cells and a decrease in superficial cells are observed. Women in early menopause typically have a maturation index of 65 parabasal cells, 30 intermediate cells and 5 superficial cells. As women age, parabasal cells will continue to increase, and the maturation index may eventually consist entirely of parabasal cells.",
"     </li>",
"     <li>",
"      Microscopic examination - Microscopic evaluation of a vaginal smear allows the clinician to identify the loss of superficial cells associated with atrophy, while at the same time, rules out the possibility of infection as an underlying cause of the vaginal symptoms. As discussed above, the wet smear shows small, rounded parabasal epithelial cells (characterized by large nuclei). In addition, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"       lactobacillus",
"      </a>",
"      -dominated flora is replaced by a mixed flora of gram-negative rods and gram-positive cocci. Large numbers of polymorphonuclear leukocytes may be present, especially if there is inflammation or infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"       \"Approach to women with symptoms of vaginitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cervical cytology - Findings on cervical cytology in women with atrophic vaginitis can mimic those observed in women with squamous intraepithelial lesions, and can even be confused with cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/16\">",
"       16",
"      </a>",
"      ]. Atrophic epithelium is often characterized by nuclear enlargement, which meets one of the pathologic criteria for atypical squamous cells and low grade squamous intraepithelial lesions. For this reason, hypoestrogenic women with atypical squamous cells and low grade squamous intraepithelial lesions may be treated with topical estrogen before further cytological follow-up. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"       \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"       \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum hormone levels - Measurement of the circulating estradiol level is usually not necessary and should be ordered only when the diagnosis of a hypoestrogenic state is in doubt. Serum estradiol levels of less than 20",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      support a clinical diagnosis of a hypoestrogenic state; however, estradiol values are very laboratory dependent and most assays for estradiol have been developed to measure premenopausal levels and are neither sufficiently sensitive nor reliable for diagnosis of hypoestrogenic states. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"       \"Clinical manifestations and diagnosis of menopause\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultrasonography of uterine lining - A thin endometrial stripe, measuring less than 4 to 5 mm on transvaginal ultrasound, suggests a hypoestrogenic state and supports the clinical diagnosis of vaginal atrophy. However, this test is expensive and should not be ordered for the sole purpose of confirming urogenital atrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"       \"Evaluation of the endometrium for malignant or premalignant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of symptomatic urogenital atrophy includes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8039/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal infections (eg, candidiasis, bacterial vaginosis, trichomoniasis, desquamative inflammatory vaginitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"       \"Approach to women with symptoms of vaginitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local reactions to environmental agents (eg, perfumes, deodorants, soaps, panty liners, perineal pads, spermicides, lubricants, or tight",
"      <span class=\"nowrap\">",
"       fitting/synthetic",
"      </span>",
"      clothing). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=see_link\">",
"       \"Dermatitis of the vulva\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vulvovaginal lichen planus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"       \"Vulvar lichen planus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vulvar lichen sclerosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"       \"Vulvar lichen sclerosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genital tract ulcers or fissures may be due to systemic disease; in women with genital tract bleeding, malignancy should be excluded. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link\">",
"       \"Differential diagnosis of vulvar lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"       \"Overview of causes of genital tract bleeding in women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=see_link&amp;anchor=H55#H55\">",
"       \"Differential diagnosis of vulvar lesions\", section on 'Ulcer/fissure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of vulvovaginal atrophy is discussed separately. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/2/13346?source=see_link\">",
"       \"Patient information: Atrophic vaginitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaginal atrophy (also referred to as vulvovaginal atrophy, urogenital atrophy, or atrophic vaginitis) caused by estrogen loss often results in urogenital symptoms. Vaginal atrophy occurs primarily in menopausal women, but may also occur during other hypoestrogenic states (eg, lactation, while taking an antiestrogenic medication). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic vaginal atrophy occurs in approximately 40 percent of menopausal women. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations include vaginal dryness, burning, pruritus, discharge, bleeding, and dyspareunia. Urinary tract symptoms (eg, frequency, recurrent infection) may also occur. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of atrophic vaginitis is clinical, based upon characteristic symptoms and findings on history and physical examination (pale, dry, thin vaginal epithelium that is smooth and shiny with loss of most rugation). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pH of &ge;5 of the vaginal vault in the absence of other causes, such as infection or semen, can be considered an indicator of vaginal atrophy due to estrogen deficiency. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/1\">",
"      Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/2\">",
"      Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000; 61:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/3\">",
"      Castelo-Branco C, Cancelo MJ, Villero J, et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52 Suppl 1:S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/4\">",
"      Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997; 314:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/5\">",
"      Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006; 91:3791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/6\">",
"      Greendale GA, Judd HL. The menopause: health implications and clinical management. J Am Geriatr Soc 1993; 41:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/7\">",
"      Forsberg JG. A morphologist's approach to the vagina--age-related changes and estrogen sensitivity. Maturitas 1995; 22 Suppl:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/8\">",
"      Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/9\">",
"      Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 Suppl 12B:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/10\">",
"      Beard MK. Atrophic vaginitis. Can it be prevented as well as treated? Postgrad Med 1992; 91:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/11\">",
"      North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/12\">",
"      Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004; 26:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/13\">",
"      Oriba HA, Maibach HI. Vulvar transepidermal water loss (TEWL) decay curves. Effect of occlusion, delipidation, and age. Acta Derm Venereol 1989; 69:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/14\">",
"      Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. Maturitas 1995; 21:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/15\">",
"      Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001; 21:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8039/abstract/16\">",
"      Selvaggi SM. Atrophic vaginitis versus invasive squamous cell carcinoma on ThinPrep cytology: can the background be reliably distinguished? Diagn Cytopathol 2002; 27:362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5464 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-6ABA7822FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8039=[""].join("\n");
var outline_f7_54_8039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H719871\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5464|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 1\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21537\" title=\"figure 2\">",
"      Vaginal epithelium in menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/59/35760\" title=\"figure 3\">",
"      STRAW staging system for reproductive aging women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5464|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/0/10245\" title=\"picture 1\">",
"      Atrophic vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/53/849\" title=\"picture 2\">",
"      Speculum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=related_link\">",
"      Dermatitis of the vulva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20618?source=related_link\">",
"      Differential diagnosis of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/2/13346?source=related_link\">",
"      Patient information: Atrophic vaginitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16218?source=related_link\">",
"      Preparations for postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1380?source=related_link\">",
"      Urethral caruncle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8040="Treatment of bilateral atherosclerotic renal artery stenosis";
var content_f7_54_8040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of bilateral atherosclerotic renal artery stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8040/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8040/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8040/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8040/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/54/8040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal artery stenosis is a relatively common cause of hypertension, but only in certain settings. The incidence of this disorder is probably less than 1 percent in patients with mild hypertension, but rises to as high as 10 to 40 percent in patients with acute (even if superimposed on a preexisting elevation in blood pressure), severe, or refractory hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two major causes of the renal arterial lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atherosclerosis &mdash; Atherosclerosis primarily affects men over the age of 45 and usually involves the aortic orifice or the proximal main renal artery. This disorder is particularly common in patients with diffuse atherosclerosis, but can occur as a relatively isolated renal lesion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H3#H3\">",
"       \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Association with systemic atherosclerosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia &mdash; In contrast to atherosclerosis, fibromuscular dysplasia (FMD) most often affects women under the age of 50 and typically involves the distal main renal artery or the intrarenal branches (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link\">",
"       \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bilateral atherosclerotic renal artery stenosis or unilateral disease in a single viable kidney can be associated with hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive renal dysfunction (called chronic ischemic renovascular disease). Issues related to the treatment of hypertension in patients with clinically important bilateral renal artery stenosis will be reviewed here, with an emphasis on efficacy of blood pressure control.",
"   </p>",
"   <p>",
"    The clinical features and treatment of chronic kidney disease due to atherosclerotic renovascular disease, the treatment of unilateral atherosclerotic renal artery stenosis, and screening for renovascular hypertension are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=see_link\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CLUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical findings that suggest an increased likelihood of secondary hypertension, some of which specifically suggest the presence of renovascular disease. These findings are used clinically to determine which patients should be evaluated for renovascular disease (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These clinical clues are important for a second reason in patients with renovascular disease that is diagnosed on an imaging study performed for some other reason. In such patients, the absence of any of these clues makes it much less likely that the renovascular disease is responsible for hypertension, if present, and therefore makes benefit from percutaneous or surgical intervention less likely.",
"   </p>",
"   <p>",
"    This is an important issue since bilateral (or unilateral) atherosclerotic renovascular disease can be an incidental finding on angiography for peripheral artery disease, occurring in patients with little or no hypertension and no progressive renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Such patients do not require therapy directed at the renal vasculature, since there is no evidence that revascularization will improve renal or other outcomes in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ]. However, some develop progressive disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Progression of stenosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H16699645#H16699645\">",
"     \"Establishing the diagnosis of renovascular hypertension\", section on 'Incidental lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calculation of the resistive index on duplex Doppler ultrasonography is another method that might identify patients who would be more likely to benefit from intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the test results vary with operator experience and testing should ideally be performed in high-volume accredited laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H16699507#H16699507\">",
"     \"Establishing the diagnosis of renovascular hypertension\", section on 'Resistive index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of renal artery stenosis is made by imaging studies in patients thought to be at risk Issues related to screening and diagnostic tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTOR REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atherosclerotic renovascular disease have a high rate of systemic atherosclerosis and are at increased risk for adverse cardiovascular outcomes. As a result, they are considered to have a coronary artery disease equivalent and should be treated according to current guidelines for secondary prevention of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of hemodynamically significant stenosis is established, with both vessels showing more than a 75 percent stenosis, there are three therapeutic alternatives:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical therapy with antihypertensive drugs",
"     </li>",
"     <li>",
"      Percutaneous angioplasty, usually with stent placement",
"     </li>",
"     <li>",
"      Surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally agree with the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on peripheral artery disease, which were produced in collaboration with major vascular medicine, vascular surgery, and interventional radiology societies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical therapy for control of hypertension is indicated in all patients with bilateral renal artery stenosis (or unilateral stenosis in a single viable kidney) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Revascularization, usually by percutaneous angioplasty with stenting, may be considered in patients with persistent hypertension who have one or more of the clinical features that suggest that the stenosis plays an important role in the elevation in blood pressure (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    ). Surgery is primarily warranted for correction of complex lesions.",
"   </p>",
"   <p>",
"    The following discussion will review the antihypertensive response to therapy in patients with bilateral renal artery stenosis. The use of angioplasty or surgery to preserve renal function in such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral renal ischemia induces activation of the renin-angiotensin-aldosterone system and promotes sodium retention with resultant volume expansion; both of these factors contribute to the ensuing rise in BP. As a result, the combination of a diuretic and an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) can control the hypertension in most patients, and is likely to be more effective than other antihypertensive agents.",
"   </p>",
"   <p>",
"    The major problem with this regimen is a hemodynamically-mediated decline in glomerular filtration rate (GFR) as detected clinically by a rise in serum creatinine. Lowering the systemic BP will tend to reduce the intraglomerular pressure below normal because of the stenotic lesion. The usual autoregulatory response in this setting consists in part of maintaining the intraglomerular pressure and therefore the GFR by an angiotensin II-mediated preferential increase in resistance at the efferent (postcapillary) arteriole (",
"    <a class=\"graphic graphic_figure graphicRef57043 \" href=\"UTD.htm?32/29/33245\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/7\">",
"     7",
"    </a>",
"    ]. Blocking angiotensin II formation with an ACE inhibitor or ARB will blunt this autoregulatory response and tend to reduce the GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/7\">",
"     7",
"    </a>",
"    ]. This effect is more pronounced with diuretic-induced volume depletion, since the hypovolemia-induced increase in angiotensin II levels makes maintenance of the GFR more angiotensin II-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is a rise in the serum creatinine concentration in most patients with severe bilateral renovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/8\">",
"     8",
"    </a>",
"    ] and some of those with less severe disease. However, these observations do not mean that ACE inhibitors or ARBs are contraindicated in this disorder as long as the patient is carefully monitored. The decline in GFR is small in most patients, with a large increase in the serum creatinine concentration occurring in less than 5 to 10 percent of cases. Furthermore, renal function can be improved in many patients by discontinuing the diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/9\">",
"     9",
"    </a>",
"    ] and in most cases by discontinuing the ACE inhibitor or ARB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients with severe bilateral disease have a significant increase in serum creatinine following BP reduction with any antihypertensive agent (",
"    <a class=\"graphic graphic_figure graphicRef75208 \" href=\"UTD.htm?25/35/26173\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/11\">",
"     11",
"    </a>",
"    ]. These patients cannot have both BP control and stable renal function, and either angioplasty or surgery must be performed.",
"   </p>",
"   <p>",
"    There are two concerns in patients who respond to medical therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic normalization of the systemic pressure might eventually lead to ischemic atrophy due to the reduced renal perfusion pressure distal to the stenosis. The risk of this complication and whether it is more likely to occur with an ACE inhibitor are currently unresolved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of unilateral atherosclerotic renal artery stenosis\", section on 'Loss of functional renal mass in the stenotic kidney'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progression of stenosis in those with atherosclerotic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Progression of stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in which repeat renal arteriography or Duplex ultrasonography is performed have shown that progressive stenosis is relatively common (eg, as much as 30 to 60 percent at four to seven years) in patients with atherosclerotic renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Progression is more likely in patients with bilateral stenosis or stenosis of a solitary functioning kidney. Patients with atherosclerotic renovascular disease also have an increased rate of extrarenal atherosclerosis and as much as a two- to four-fold increase in cardiovascular events.",
"   </p>",
"   <p>",
"    These issues of progression of renal artery stenosis and increased cardiovascular risk are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Progression of renal artery lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Association with systemic atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk associated with progressive disease was illustrated in a retrospective report of 68 patients with high grade (&gt;70 percent) atherosclerotic renal artery stenosis who did not undergo revascularization, 21 of whom had bilateral stenosis or stenosis in a single kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/13\">",
"     13",
"    </a>",
"    ]. Among these 21 patients (average age 75 years), the average serum creatinine concentration was 1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (141",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    compared to 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (115",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for those with unilateral disease.",
"   </p>",
"   <p>",
"    At three year follow-up, the mean blood pressure was",
"    <span class=\"nowrap\">",
"     160/81",
"    </span>",
"    mmHg. An increase of at least 50 percent in the serum creatinine concentration was observed in 4 of the 21 patients, two of whom progressed to end-stage disease. The remaining 17 patients had stable renal function. However, the mortality rate was 43 percent, due most commonly to myocardial infarction or heart failure. The outcomes were better in patients with unilateral disease: 13 percent had renal progression and 21 percent died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Percutaneous transluminal angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due in part to the frequent presence of ostial or completely occluding lesions, both of which are less amenable to routine percutaneous transluminal angioplasty (PTA), PTA alone (ie, without stenting) is generally less successful and associated with more complications (such as atheroemboli) in bilateral as compared to unilateral atherosclerotic renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/14\">",
"     14",
"    </a>",
"    ]. A 2006 systematic review of management strategies for renal artery stenosis concluded that, although the published evidence was inadequate to draw any robust conclusions, improved blood pressure outcomes were observed with PTA versus medical therapy, particularly in those with bilateral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence of clinical atheroembolic disease following renal artery angioplasty is thought to be relatively low, but is probably higher in patients with bilateral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\", section on 'Procedural complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Stent placement and outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observational studies showed a high rate of success with stent placement in patients with ostial atherosclerotic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. In contrast, three randomized trials showed",
"    <strong>",
"     no benefit",
"    </strong>",
"    from angioplasty with stenting compared to medical therapy with respect to both blood pressure control and renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/22-24\">",
"     22-24",
"    </a>",
"    ] and no difference in cardiovascular events and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Issues related to renal function after intervention are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Stent placement and outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these trials had several important limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of patients with true (more than 70 percent) bilateral stenosis was limited as many lesions had 50 to 70 percent stenosis, which is probably not hemodynamically significant. In addition, in one trial, many patients were falsely identified as having renal artery stenosis greater than 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The patients were not selected because they had clinical clues suggesting that the stenosis was likely to contribute to the hypertension (",
"      <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"       table 1",
"      </a>",
"      ). This is a potentially important issue since bilateral (or unilateral) atherosclerotic renovascular disease can be an incidental finding on angiography for peripheral artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest trial, ASTRAL, included 806 patients with either unilateral or bilateral atherosclerotic renal artery stenosis who were randomly assigned to either medical therapy alone or medical therapy plus revascularization (95 percent with angioplasty with stent placement, 5 percent was angioplasty alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/22\">",
"     22",
"    </a>",
"    ]. A subgroup analysis of 163 patients with bilateral stenoses greater than 70 percent or a unilateral stenosis greater than 70 percent in a solitary functioning kidney showed no significant difference between the two groups in the rate of progression of the serum creatinine (the primary end point) at a median follow-up of almost three years.",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of peripheral artery disease, published before the ASTRAL trial, recommended stenting for ostial atherosclerotic lesions in patients who have clinical clues suggesting that the renovascular disease is likely to be responsible for hypertension that is not well controlled with medical therapy (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ]. Based upon the available data, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    performing percutaneous transluminal angioplasty with stenting in patients who do not meet these criteria because the likelihood of benefit is small and the risk of procedural complications is relatively high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Procedural complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technical complication rate with percutaneous transluminal angioplasty with or without stenting is between 5 and 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/10,19,22-26\">",
"     10,19,22-26",
"    </a>",
"    ]. Most of the complications are relatively minor and include puncture site hematoma and renal artery dissection. However, more serious problems can arise, including death, renal artery thrombosis or perforation (often requiring surgery) and acute renal failure due to atheroembolic disease (which may be irreversible) or to a reaction to the radiocontrast agent (which is reversible).",
"   </p>",
"   <p>",
"    In the ASTRAL trial described above, there were 38 complications that occurred within 24 hours of procedure in 31 of the 359 patients (9 percent) who underwent revascularization with stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/22\">",
"     22",
"    </a>",
"    ]. Nineteen of these events were serious, including pulmonary edema and myocardial infarction; there were five renal embolizations, four renal arterial occlusions, four renal artery perforations, one femoral-artery aneurysm, and three patients with clinically significant cholesterol embolization. Among 280 patients who underwent revascularization and for whom data were available, 20 percent had an adverse event between 24 hours and one month. These included two deaths, four cases of groin hematoma or hemorrhage, five cases of acute kidney injury, and one renal artery occlusion.",
"   </p>",
"   <p>",
"    The rate of embolization that is not clinically detectable is substantially higher since studies of renal artery angioplasty with stenting using distal embolic protection devices reported grossly visible material in 45 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Distal embolization of atheromatous material or thrombus could partially negate the benefits of revascularization on kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/29\">",
"     29",
"    </a>",
"    ]. Whether performing the procedure with distal embolic protection results in improved kidney function is uncertain, as available reports are uncontrolled [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/23,30\">",
"     23,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical revascularization (or removal of a completely occluded atrophic kidney) appears to have similar efficacy to percutaneous transluminal angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A number of different operative procedures can be used. Most operations involve either bilateral repair or unilateral repair with contralateral nephrectomy of a nonfunctioning, atrophic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended surgery in patients with atherosclerotic renal artery stenosis who have indications for revascularization (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    ), particularly if they have multiple small renal arteries, early primary branching of the main renal artery, or require aortic reconstruction near the renal arteries for other indications (eg, aneurysm repair or severe aortoiliac occlusive disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     In-hospital mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of surgery in these settings must be weighed against the operative mortality rate. In-hospital mortality following renovascular surgery in most reports has been between 3 and 7 percent, with the risk being increased in patients with diffuse atherosclerosis and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/1,10,32\">",
"     1,10,32",
"    </a>",
"    ]. However, most of these studies came from high-volume referral centers.",
"   </p>",
"   <p>",
"    A higher in-hospital mortality rate of 10.1 percent for atherosclerotic disease was noted in an analysis of over 6600 renal artery bypass graft procedures performed for hypertension or ischemic nephropathy from 2000 to 2004 in the United States; almost 70 percent were performed in teaching hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/33\">",
"     33",
"    </a>",
"    ]. Independent risk factors for in-hospital mortality (relative risk 1.6 to 2.2) were advanced age and a history of chronic kidney disease, heart failure, or chronic lung disease. The mortality rate was similar with renal bypass graft alone or combined with abdominal aortic aneurysm repair or aortobifemoral bypass. There were no deaths in 105 procedures fibromuscular dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of fibromuscular dysplasia of the renal arteries\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations provide support for percutaneous transluminal angioplasty with stenting as the preferred approach in most patients with bilateral atherosclerotic renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/10,33\">",
"     10,33",
"    </a>",
"    ], since hypertension and renal outcomes appear to be similar to those attained with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/31\">",
"     31",
"    </a>",
"    ]. This would not apply to patients who require aortic reconstruction near the renal arteries for other indications (eg, aneurysm repair or severe aortoiliac occlusive disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ]. Symptomatic coronary or cerebrovascular disease may need to be repaired prior to renovascular surgery, a regimen that can reduce overall mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=see_link\">",
"       \"Patient information: Renovascular hypertension (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with atherosclerotic renovascular disease should be treated with risk factor reduction according to current guidelines for secondary prevention of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for the control of hypertension in patients with atherosclerotic bilateral renal artery includes both medical and interventional therapy. Interventions aimed at preserving renal function in patients with bilateral renal artery stenosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hypertension control, we recommend an ACE inhibitor or angiotensin II receptor blocker (ARB), often in combination with diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/34\">",
"     34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     Chlorthalidone",
"    </a>",
"    is the preferred thiazide diuretic, but a loop diuretic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    ), may be required in patients who have chronic kidney disease with a significantly reduced glomerular filtration rate. Long-acting calcium channel blockers and beta blockers are also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Interventional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transluminal angioplasty with stenting is the preferred nonsurgical intervention. Three randomized trials, all with serious flaws, found no improvement in blood pressure, renal, or cardiovascular outcomes in patients with atherosclerotic renal artery stenosis who were treated with percutaneous transluminal angioplasty and stent placement. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Stent placement and outcomes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We agree with the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of peripheral artery disease, which recommended percutaneous transluminal angioplasty with stenting for ostial atherosclerotic lesions in patients who have clinical clues suggesting that the renovascular disease is likely to be responsible for hypertension that is not well controlled with optimal medical therapy (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H517662#H517662\">",
"     \"Establishing the diagnosis of renovascular hypertension\", section on 'Indications for testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the available data, we recommend",
"    <strong>",
"     not",
"    </strong>",
"    performing percutaneous transluminal angioplasty in patients who do not meet these criteria because the likelihood of benefit is small and the risk of procedural complications is relatively high. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Procedural complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We agree with the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, which recommended surgery in patients with atherosclerotic renal artery stenosis who have clinical indications for revascularization, particularly if they have multiple small renal arteries, early primary branching of the main renal artery, or require aortic reconstruction near the renal arteries for other indications (eg, aneurysm repair or severe aortoiliac occlusive disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/1\">",
"      Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/2\">",
"      Choudhri AH, Cleland JG, Rowlands PC, et al. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ 1990; 301:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/3\">",
"      Leertouwer TC, Pattynama PM, van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int 2001; 59:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/4\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/5\">",
"      Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/6\">",
"      Dworkin LD, Jamerson KA. Is renal artery stenting the correct treatment of renal artery stenosis? Case against angioplasty and stenting of atherosclerotic renal artery stenosis. Circulation 2007; 115:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/7\">",
"      Hall JE, Guyton AC, Jackson TE, et al. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977; 233:F366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/8\">",
"      Hricik DE, Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1990; 1:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/9\">",
"      Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/10\">",
"      Dworkin LD, Cooper CJ. Clinical practice. Renal-artery stenosis. N Engl J Med 2009; 361:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/11\">",
"      Novick AC. Current concepts in the management of renovascular hypertension and ischemic renal failure. Am J Kidney Dis 1989; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/12\">",
"      Pohl MA, Novick AC. Natural history of atherosclerotic and fibrous renal artery disease: clinical implications. Am J Kidney Dis 1985; 5:A120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/13\">",
"      Ch&aacute;bov&aacute; V, Schirger A, Stanson AW, et al. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 2000; 75:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/14\">",
"      Marshall FI, Hagen S, Mahaffy RG, et al. Percutaneous transluminal angioplasty for atheromatous renal artery stenosis--blood pressure response and discriminant analysis of outcome predictors. Q J Med 1990; 75:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/15\">",
"      Balk E, Raman G, Chung M, et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med 2006; 145:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/16\">",
"      Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/17\">",
"      Burket MW, Cooper CJ, Kennedy DJ, et al. Renal artery angioplasty and stent placement: predictors of a favorable outcome. Am Heart J 2000; 139:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/18\">",
"      Watson PS, Hadjipetrou P, Cox SV, et al. Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. Circulation 2000; 102:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/19\">",
"      Rocha-Singh K, Jaff MR, Rosenfield K, ASPIRE-2 Trial Investigators. Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. J Am Coll Cardiol 2005; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/20\">",
"      Cooper CJ, Murphy TP. Is renal artery stenting the correct treatment of renal artery stenosis? The case for renal artery stenting for treatment of renal artery stenosis. Circulation 2007; 115:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/21\">",
"      Corriere MA, Pearce JD, Edwards MS, et al. Endovascular management of atherosclerotic renovascular disease: early results following primary intervention. J Vasc Surg 2008; 48:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/22\">",
"      ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/23\">",
"      Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009; 150:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/24\">",
"      van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000; 342:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/25\">",
"      Plouin PF, Chatellier G, Darn&eacute; B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/26\">",
"      Blum U, Krumme B, Fl&uuml;gel P, et al. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med 1997; 336:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/27\">",
"      Holden A, Hill A, Jaff MR, Pilmore H. Renal artery stent revascularization with embolic protection in patients with ischemic nephropathy. Kidney Int 2006; 70:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/28\">",
"      Edwards MS, Craven BL, Stafford J, et al. Distal embolic protection during renal artery angioplasty and stenting. J Vasc Surg 2006; 44:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/29\">",
"      Dorros G, Jaff M, Mathiak L, et al. Renal function and survival after renal artery stent revascularization may be influenced by embolic debris. J Invasive Cardiol 2004; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/30\">",
"      Conlon PJ, O'Riordan E, Kalra PA. New insights into the epidemiologic and clinical manifestations of atherosclerotic renovascular disease. Am J Kidney Dis 2000; 35:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/31\">",
"      Weibull H, Bergqvist D, Bergentz SE, et al. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. J Vasc Surg 1993; 18:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/32\">",
"      Aurell M, Jensen G. Treatment of renovascular hypertension. Nephron 1997; 75:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/33\">",
"      Modrall JG, Rosero EB, Smith ST, et al. Operative mortality for renal artery bypass in the United States: Results from the National Inpatient Sample. J Vasc Surg 2008; 48:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8040/abstract/34\">",
"      Hackam DG, Spence JD, Garg AX, Textor SC. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension 2007; 50:998.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3836 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8040=[""].join("\n");
var outline_f7_54_8040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CLUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTOR REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Progression of stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Percutaneous transluminal angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Stent placement and outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Procedural complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - In-hospital mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Interventional therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3836|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/29/33245\" title=\"figure 1\">",
"      A2 and autoregulation of GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/35/26173\" title=\"figure 2\">",
"      Nitroprusside in RA stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42604\" title=\"table 1\">",
"      Features of secondary HTN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromuscular dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=related_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=related_link\">",
"      Treatment of fibromuscular dysplasia of the renal arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29369?source=related_link\">",
"      Treatment of unilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8041="Elvitegravir, cobicistat, tenofovir and emtricitabine: Drug information";
var content_f7_54_8041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Elvitegravir, cobicistat, tenofovir and emtricitabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/19/14645?source=see_link\">",
"    see \"Elvitegravir, cobicistat, tenofovir and emtricitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14941863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14944840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Stribild&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16337655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Stribild&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14941868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Integrase Inhibitor;",
"     </li>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside);",
"     </li>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleotide)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14944954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV-1:",
"     </b>",
"     Oral: One tablet once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as an alternative regimen for antiretroviral-naive patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;70 mL/minute (DHHS, 2012b).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14944955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14944959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;70 mL/minute: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;70 mL/minute at initiation of therapy: Initial use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute during therapy: Continued use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ESRD requiring dialysis: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14944960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment (Child-Pugh class C): Use is not recommended (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14969757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stribild&trade;: Elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F14944847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14944970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14941870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14943816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported for combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (16%), diarrhea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Proteinuria (39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Abnormal dreams (9%), headache (7%), fatigue (5%), dizziness (3%), insomnia (3%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Cholesterol increased (grades 3/4: &le;1%), triglycerides increased (grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Amylase increased (2%), flatulence (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: CPK increased (5%), fractures (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (7%), hematuria (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Fanconi syndrome, immune reconstitution syndrome, renal failure",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14944852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use of alfuzosin, cisapride, ergot derivatives (eg, dihydroergotamine, ergotamine, methylergonovine); lovastatin, midazolam (oral), pimozide, rifampin, sildenafil (when used for pulmonary arterial hypertension), simvastatin, St John&rsquo;s wort, triazolam",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14944867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone mineral density: Use of tenofovir has been associated with decreases in bone mineral density, increases in biochemical markers of bone metabolism, and osteomalacia. Increased serum parathyroid hormone and 1,25 Vitamin D levels have been noted with tenofovir use. Consider monitoring of bone density in patients at risk for osteopenia, osteoporosis, or with a history of pathologic fractures; consider calcium and vitamin D supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues (eg, tenofovir), including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, prolonged use, or obesity) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis). Some cases of hepatotoxicity have occurred in patients with no hepatic disease prior to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy. Calculate creatinine clearance prior to initiation of therapy and monitor renal function (including recalculation of creatinine clearance, urine glucose, and protein and serum phosphorus) during therapy in all patients. Do not initiate therapy in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;70 mL/minute. Continued use is not recommended in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute. Cobicistat component inhibits tubular creatinine secretion without affecting glomerular filtration; may cause modest declines in estimated renal function early in therapy which then stabilize; closely monitor patients with &gt;0.4 mg/dL increase of serum creatinine from baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Safety and efficacy during coinfection of HIV and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of antiretroviral therapy. Not indicated for treatment of chronic hepatitis B.",
"     </b>",
"     All patients with HIV should be tested for HBV prior to initiation of treatment. Caution in patients with known or suspected hepatitis B or C infection (monitoring of liver function is recommended); monitor hepatic function closely for several months following discontinuation. If appropriate, initiation of HBV therapy may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: No dosage adjustment is required in mild or moderate (Child-Pugh Class A or B) hepatic impairment. Use is not recommended in severe hepatic impairment (Child-Pugh Class C); has not been studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV treatment: Appropriate use: Use only in treatment-naive adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Concurrent therapy: Avoid concurrent use with adefovir or lamivudine-containing products or other emtricitabine-, and/or tenofovir-containing products.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14975223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14975221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Elvitegravir. Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Cobicistat may increase the serum concentration of AtorvaSTATin.  Management: Initiate atorvastatin at the lowest starting dose and titrate up slowly as needed while monitoring closely for evidence of atorvastatin adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Cobicistat may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adults who have been on elvitegravir/cobicistat/emtricitabine/tenofovir for at least 10 days.  Stop bosentan for at least 36 hrs before starting the combo product; wait at least 10 days before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Cobicistat. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Elvitegravir. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Cobicistat may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin. Management: In patients with an estimated creatinine clearance of 50 to 60 mL/min, the clarithromycin dose needs to be reduced by 50% when used together with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ClonazePAM: Cobicistat may increase the serum concentration of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Cobicistat may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor like cobicistat.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Cobicistat may decrease the serum concentration of Contraceptives (Estrogens).  Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Elvitegravir may decrease the serum concentration of Contraceptives (Estrogens).  Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Cobicistat may increase the serum concentration of Contraceptives (Progestins).  Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): May decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): May decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Cobicistat may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Cobicistat may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Cobicistat may increase the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): Cobicistat may increase the serum concentration of Fluticasone (Nasal).  Management: Consider using an alternative nasal corticosteroid when possible, partiularly for longer-term concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): Cobicistat may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin-Phenytoin: May decrease the serum concentration of Cobicistat. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin-Phenytoin: May decrease the serum concentration of Elvitegravir. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Elvitegravir. Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Cobicistat may increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Cobicistat.  Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Elvitegravir. Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Cobicistat may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Cobicistat.  Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Cobicistat may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Cobicistat may increase the serum concentration of Midazolam.  Management: Oral midazolam is contraindicated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.  IV midazolam should only be used with caution, close monitoring, and consideration of lower IV midazolam doses.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Cobicistat. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Elvitegravir. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Cobicistat. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Elvitegravir. Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: May decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: May decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifapentine: May decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifapentine: May decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: Cobicistat may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Cobicistat may increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Cobicistat may increase the serum concentration of Sildenafil.  Management: Use of sildenafil for pulmonary hypertension with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product is contraindicated.  Used for erectile dysfunction, sildenafil doses should be limited to 25 mg per 48 hrs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Cobicistat may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate product vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telithromycin: Cobicistat may increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Cobicistat.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Cobicistat may increase the serum concentration of TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Cobicistat may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Cobicistat may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Cobicistat may increase the serum concentration of Vardenafil.  Management: Recommendations regarding use of vardenafil with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate product vary based on specific vardenafil brand and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Elvitegravir. Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Cobicistat may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Cobicistat.  Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Cobicistat may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Elvitegravir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14944848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14944849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies following administration of the individual agents contained in this combination product. Also see individual agents. Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14944850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14944851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F14944969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with a meal. Consider calcium and vitamin D supplementation in patients with history of bone fracture or osteopenia.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Stribild Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-150-200-300 mg (30): $2810.96",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14944984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, reticulocyte count, serum creatine kinase, CD4 count, HIV RNA plasma levels, renal and hepatic function tests, urine glucose and protein, serum phosphorus (routinely in patients at risk for renal impairment); bone density (long-term); testing for HBV is recommended prior to the initiation of antiretroviral therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients with HIV and HBV coinfection should be monitored for several months following tenofovir discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14944909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Integrase strand transfer inhibitor, CYP3A enzyme inhibitor plus nucleoside and nucleotide reverse transcriptase inhibitor combination; the viral cDNA strand produced by reverse transcriptase is processed and inserted into the human genome by the enzyme HIV-1 integrase. Elvitegravir inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA. Cobicistat inhibits enzymes of the CYP3A subfamily and enhances systemic exposure to elvitegravir. Emtricitabine is a cytosine analogue and tenofovir disoproxil fumarate (TDF) is an analog of adenosine 5'-monophosphate. Emtricitabine and tenofovir interfere with HIV viral RNA dependent DNA polymerase activities resulting in inhibition of viral replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14944926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: AUC of elvitegravir and tenofovir increases with food; emtricitabine and cobicistat not affected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Elvitegravir (99%); cobicistat (98%); emtricitabine (&lt;4%); tenofovir (&lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Elvitegravir: By CYP3A enzymes and also hepatic glucuronidation mediated by UGT1A1/3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cobicistat: By CYP3A enzymes and to a minor extent CYP2D6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Emtricitabine and tenofovir: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Elvitegravir ~13 hours; cobicistat ~4 hours; emtricitabine ~10 hours; tenofovir ~17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~3 hours (range: 2-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Elvitegravir: Feces (~95%), urine (~7%); cobicistat: Feces (~86%), urine (~8%); emtricitabine: Feces (14%), urine (86%); tenofovir: Urine (70% to 80%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DeJesus E, Rockstroh JK, Henry K, et al, \"Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Co-Formulated Emtricitabine and Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 379(9835):2429-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8041/abstract-text/22748590/pubmed\" id=\"22748590\" target=\"_blank\">",
"        22748590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Statement Update: &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; September 18, 2012b. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\" July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sax PE, DeJesus E, Mills A, et al, \"Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Versus Co-Formulated Efavirenz, Emtricitabine, and Tenofovir for Initial Treatment of HIV-1 Infection: A Randomised, Double-Blind, Phase 3 Trial, Analysis of Results After 48 Weeks,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 379(9835):2439-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/54/8041/abstract-text/22748591/pubmed\" id=\"22748591\" target=\"_blank\">",
"        22748591",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86285 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8041=[""].join("\n");
var outline_f7_54_8041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14941863\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16337655\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14941868\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944954\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944955\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944959\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944960\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14969757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944847\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944970\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14941870\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943816\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944852\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944867\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975223\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14975221\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944848\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944849\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944850\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944851\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944969\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570450\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944984\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944909\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14944926\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86285|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/19/14645?source=related_link\">",
"      Elvitegravir, cobicistat, tenofovir and emtricitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8042="Osteoclast inhibition in the management of bone metastases from breast cancer";
var content_f7_54_8042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteoclast inhibition in the management of bone metastases from breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8042/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8042/contributors\">",
"     Catherine Van Poznak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8042/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8042/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/54/8042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/54/8042/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/54/8042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, breast cancer is the most frequently diagnosed cancer, and the leading cause of cancer death in females. In the United States, breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 40 to 59 years.",
"   </p>",
"   <p>",
"    The management of patients with metastatic breast cancer (MBC) involving the bone integrates antineoplastic therapies, with local therapies, such as surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy, osteoclast inhibitors, and supportive interventions, such as analgesics. Drugs that decrease skeletal complications in patients with bone metastases from MBC, including bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , are presented here; antineoplastic therapies, local therapies, and adjunctive therapies are discussed separately. An extensive discussion on the risks of therapy with bone modifying agents in patients with advanced cancer is also covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link\">",
"       \"Metastatic breast cancer: Local treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"       \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BONE METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When breast cancer metastasizes, bone is the most common site of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/1\">",
"     1",
"    </a>",
"    ]. Postmortem analysis has demonstrated that approximately 70 percent of patients dying from breast cancer have evidence of bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/2\">",
"     2",
"    </a>",
"    ]. Risk factors for the development of bone metastases include greater than four involved axillary lymph nodes at initial diagnosis, primary tumor greater than 2 cm, estrogen receptor positive cancer, and younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average life expectancy of patients with metastatic breast cancer involving the bone is estimated at two years, with approximately 20 percent of patients living five years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Those with bone only involvement at presentation may have a longer survival, estimated at 72 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/7\">",
"     7",
"    </a>",
"    ]. Bone metastases can be associated with pain, particularly with motion, thereby significantly affecting the patient's quality of life. The frequency of bone metastases and the expected survival of patients with metastatic breast cancer make management of bone metastases a clinically important factor in the care of these patients.",
"   </p>",
"   <p>",
"    Treatment options for breast cancer bone metastases include local therapy (surgery, external beam radiation [EBRT], and radiofrequency ablation [RFA]), systemic anticancer therapy (endocrine therapy, chemotherapy, monoclonal antibodies, and other targeted therapies), and bone-targeting agents, such as bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , or other osteoclast inhibitors, and radioisotopes. Surgery is typically reserved for the palliative treatment of epidural spinal cord",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nerve compression syndromes and to stabilize or prevent bone fractures. EBRT may be used to treat bone lesions associated with pain or at an increased risk for fracture. An overview of the treatment of metastatic breast cancer and local therapeutic options are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=see_link\">",
"     \"Metastatic breast cancer: Local treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms of bone metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which bone metastases develop and affect normal bone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=see_link\">",
"     \"Mechanisms of bone metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Skeletal-related events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases can be associated with skeletal complications, often referred to as skeletal-related events (SREs), which include fracture, need for surgery or radiation to bone, spinal cord compression, and hypercalcemia of malignancy. SREs are clinical outcomes that can be distinctly measured; hence, they are often used as endpoints within clinical trials investigating therapies for bone metastases, although not all studies include hypercalcemia of malignancy. The definition of SRE does not include pain or changes to quality of life (QOL), which are typically measured as separate outcomes in clinical trials.",
"   </p>",
"   <p>",
"    A retrospective analysis of patients with metastatic breast cancer during the period of 1981 to 1991, which was prior to the incorporation of bisphosphonate therapy, demonstrated that greater the 50 percent of women with metastatic breast cancer developed SREs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/8\">",
"     8",
"    </a>",
"    ]. Other evidence suggests that in the absence of osteoclast inhibition, one SRE occurs on an average of every three to four months in women with lytic bone metastases from breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Medications that inhibit osteoclast activity have been shown to reduce the risk of SREs, as discussed below.",
"   </p>",
"   <p>",
"    Hypercalcemia of malignancy, spinal cord compression, and radiation therapy for painful bone metastases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CALCIUM AND VITAMIN D SUPPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium and vitamin D are important to maintaining bone health. The United States Institute of Medicine put forth recommendations pertaining to calcium and vitamin D intake based on current scientific evidence about their roles in human health [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/13\">",
"     13",
"    </a>",
"    ]. The principles and guidance outlined by the Institute of Medicine apply to the general population and can be applied to those with metastatic bone disease.",
"   </p>",
"   <p>",
"    In patients with metastatic breast cancer involving the bone who are receiving potent inhibitors of osteoclast activity, there is concern for hypocalcemia occurring if there is insufficient dietary intake of calcium and a low vitamin D status. Profound inhibition of the osteoclast restricts the body&rsquo;s ability to utilize the electrolytes stored within the bone. Furthermore, breast cancer patients are at risk of being vitamin D deficient. In a review of 321 breast cancer patients treated with bisphosphonates for either low bone mass or for metastatic disease, over 50 percent were vitamin D deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/14\">",
"     14",
"    </a>",
"    ]. These individuals with vitamin D deficiency are at increased risk for hypocalcemia, a known potential side effect of osteoclast inhibition therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link&amp;anchor=H8#H8\">",
"     \"Pharmacology of bisphosphonates\", section on 'Clinical use and adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the clinical studies investigating the osteoclast inhibitors for metastatic bone disease incorporated calcium and vitamin D supplementation as part of the study treatment regimen. Therefore, to mimic the treatment regimen used in these clinical trials, patients should have correction of preexisting hypocalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D deficiency and be advised on the intake of calcium and vitamin D. The United States Food and Drug Administration (FDA) labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    all provide advice on supplementation with calcium and vitamin D in patients without contraindications for their use.",
"   </p>",
"   <p>",
"    When counseling on the use of calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D supplementation concern for the potential for hypercalcemia must also be considered. In addition, calcium supplements may associate with a small increase in cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/15\">",
"     15",
"    </a>",
"    ]. Recommendations for supplementation with calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin D need to be tailored to the individual and reassessed over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608403970\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates, as potent inhibitors of osteoclast function, reduce the morbidity of metastatic bone disease, decrease the prevalence of skeletal-related events (SREs), and improve control of bone pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Both oral (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ) and intravenous (ibandronate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ) formulations have become integral components of treatment in patients with breast cancer and bone metastases. In the United States, only two bisphosphonates, pamidronate and zoledronic acid, are FDA approved for the management of metastatic bone disease in patients with breast cancer. The risks associated with bisphosphonate therapy for patients with advanced cancer are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described below, clinical trial data, individually and in meta-analysis, has established that in women with metastatic breast cancer and clinically evident bone metastases, the use of bisphosphonates (oral or intravenous) reduces the frequency of skeletal-related events by approximately one third when compared with placebo or no bisphosphonate therapy. (See",
"    <a class=\"local\" href=\"#H608404370\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608404042\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical application of bisphosphonates to decrease the risk of SREs stemmed from their ability to inhibit bone resorption and the related bone destruction of osseous metastases. Inhibition of osteoclast activity interrupts the vicious cycle of the cell signaling between the tumor in the bone microenvironment and the osteoclasts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/20\">",
"     20",
"    </a>",
"    ]. The mechanism of action of bisphosphonates is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608404108\">",
"    <span class=\"h2\">",
"     Complications of bisphosphonate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with bisphosphonates is generally well tolerated, with less than 2 percent of patients in phase III studies experiencing serious toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/21\">",
"     21",
"    </a>",
"    ]. Complications associated with the bisphosphonates include acute phase reactions, renal insufficiency, electrolyte imbalance, ocular inflammation, and osteonecrosis of the jaw (ONJ).",
"   </p>",
"   <p>",
"    The acute phase reaction, a flu-like syndrome often with fever, chills, myalgia and arthralgias, may occur, in some degree, in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/22\">",
"     22",
"    </a>",
"    ]. When it occurs, it is typically seen within the first 48 hours of infusion and is self limiting within 24 to 48 hours. Premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or non-steroidal antiinflammatory drugs may help [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/21\">",
"     21",
"    </a>",
"    ]. On subsequent dosing, the risk of the acute phase reaction and its intensity decreases. The bisphosphonates can be associated with other inflammatory reactions including phlebitis and ocular toxicities of conjunctivitis, uveitis, scleritis, and orbital inflammation. Ocular inflammation often requires a formal ophthalmologic evaluation and further treatment with the offending bisphosphonate is often not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to maximize oral health and decrease the risk of ONJ, it is recommended that patients undergo a dental examination before initiating bisphosphonates and continue good oral hygiene throughout treatment. To assess for electrolyte and renal disturbance, laboratory monitoring of serum creatinine, calcium, magnesium, and phosphate should be performed regularly while on bisphosphonates. Renal toxicity associated with bisphosphonates may be reduced by observing recommendations for pretreatment assessment of renal function, infusion durations, optimizing hydration prior to bisphosphonate therapy, and avoiding concurrent nephrotoxic medications.",
"   </p>",
"   <p>",
"    Risks of bisphosphonate therapy in patients with malignancy, including prevention and treatment of renal toxicity and ONJ, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    is effective in reducing skeletal morbidity in patients with breast cancer and lytic bone metastases (",
"    <a class=\"graphic graphic_table graphicRef56951 \" href=\"UTD.htm?18/42/19118\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/10-12,23-25\">",
"     10-12,23-25",
"    </a>",
"    ]. In one trial, for example, 380 women with osteolytic metastases and who were receiving systemic chemotherapy were randomly assigned to pamidronate (90 mg intravenous monthly for two years) or placebo. After two years of follow-up, treatment with pamidronate significantly delayed the appearance of clinical skeletal complications (median time to first skeletal complication 14 versus 7 months), and decreased the proportion of patients in whom any skeletal complication occurred (43 percent versus 56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. There was also significantly less increase in bone pain and deterioration of performance status in the pamidronate group than in the placebo group. But pamidronate had no effect on survival. Similar results were seen in a trial of 372 women with metastatic breast cancer and lytic bone metastases who were receiving concurrent hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/12\">",
"     12",
"    </a>",
"    ]. In this trial, the time to first skeletal complication was prolonged with pamidronate (median 10.4 versus 6.9 months), and the proportion of women with skeletal complications was reduced (56 versus 67 percent).",
"   </p>",
"   <p>",
"    When used to decrease the risk of SREs in patients with bone metastases from breast cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is dosed at 90 mg infused over two hours every three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    , a high potency parenteral bisphosphonate that can be administered over a shorter time period than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , also effectively decreases the risk of skeletal events in women with breast cancer and osteolytic (and osteoblastic) metastases (",
"    <a class=\"graphic graphic_table graphicRef56951 \" href=\"UTD.htm?18/42/19118\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    was compared to placebo in a trial that randomly assigned 228 women with bone metastases from breast cancer to zoledronic acid (4 mg monthly for 15 months) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/29\">",
"     29",
"    </a>",
"    ]. The rate of SREs (30 versus 50 percent) and the time to develop a first skeletal-related event (median not reached versus 364 days) were significantly improved in the treated group. In this trial, renal adverse events were infrequent and there was no difference between treatment groups.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in comparison with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Choice of agent'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Oral bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral bisphosphonates have demonstrated efficacy in reducing the risk of SREs in patients with metastatic bone disease, and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    are licensed for this indication outside of the United States. Clodronate has been shown to reduce the incidence of hypercalcemic episodes and the number of vertebral fractures, as well as reduce the combined rate of all morbid skeletal events by 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     Ibandronate",
"    </a>",
"    is a high potency bisphosphonate that can be administered IV or orally, and both routes appear to be similarly effective and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/33\">",
"     33",
"    </a>",
"    ]. The efficacy of oral ibandronate (50 mg once daily) was shown in two placebo-controlled trials involving a total of 564 women with breast cancer and bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/34\">",
"     34",
"    </a>",
"    ]. In a pooled analysis, treatment with ibandronate was associated with a significant reduction in the overall risk of a skeletal event (hazard ratio, HR 0.62) and in the need for RT or surgery, but did not significantly reduce the incidence of vertebral or nonvertebral fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608404691\">",
"    <span class=\"h1\">",
"     DENOSUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoclast inhibition can also be obtained by targeting the receptor activator of nuclear factor kappa B ligand (RANKL) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/35\">",
"     35",
"    </a>",
"    ]. The monoclonal antibody to RANKL,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , has demonstrated efficacy in decreasing the risk of first and subsequent skeletal-related events (SREs), in patients with bone metastases from breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ]. Denosumab (120 mg subcutaneously every four weeks) is approved by the United States FDA to prevent SREs in patients with bone metastases from solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (dosed at 60 mg subcutaneously every six months) has been FDA approved for management of postmenopausal osteoporosis in women who are at high risk for fracture. Denosumab has also been studied in patients with breast and prostate cancer who are at risk for cancer therapy-induced bone loss due to endocrine therapy with aromatase inhibitors and androgen deprivation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    has been studied in patients with metastatic bone disease who have had prior exposure to bisphosphonates. A randomized phase II, open label clinical trial examined sequential osteoclast inhibiting therapy on the biochemical marker of bone resorption, urinary N-telopeptide (uNTx) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/40\">",
"     40",
"    </a>",
"    ]. This trial enrolled 111 patients with metastatic bone disease from a variety of tumors including breast cancer, who had uNTx values above 50",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    while receiving intravenous bisphosphonate therapy. They were randomly assigned to either continuing on intravenous bisphosphonate therapy or switching to denosumab (180 mg subcutaneously every four or every 12 weeks, a different regimen from the FDA approved dosing). A significantly greater percentage of patients on denosumab versus intravenous bisphosphonate reduced the uNTx to below 50",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    by week 13 (29 versus 71 percent). There were fewer on study SREs with denosumab, but this was not statistically significant (8 versus 17 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    also prevents SREs in patients with metastatic bone disease without prior intravenous bisphosphonate therapy. In a double blind phase III trial of 2046 patients with metastatic breast cancer involving the bone (NCT00321464), patients were randomly assigned to either denosumab (120 mg subcutaneous monthly and intravenous placebo) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg intravenous monthly and subcutaneous placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ]. The efficacy analysis examined non-inferiority as the primary endpoint, and superiority as a secondary endpoint. Denosumab met both of these endpoints with denosumab showing a greater delay to first on study SREs than zoledronic acid [hazard ratio (HR) 0.82, 95% CI 0.71-0.95, p&lt;0.001 (noninferiority) p=0.01 (superiority)]. Compared with zoledronic acid, denosumab extended the median time to development of first on-study SRE (32.4 versus 26.4 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ]. There was no statistical difference between denosumab and zoledronic acid in overall survival (HR 0.95, 95% CI 0.81-1.11) or time to disease progression (HR 1.00, 95% CI 0.89-1.11).",
"   </p>",
"   <p>",
"    The toxicity evaluations in this trial demonstrated that the incidence of adverse events and serious adverse events are similar with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ]. There was no significant difference in osteonecrosis of the jaw, seen in 20 patients in the denosumab arm (2 percent) versus 14 patients receiving zoledronic acid (1.4 percent), but severe (grade 3 and 4) renal toxicity (2.2 versus 0.4 percent) and acute-phase reactions (27.3 versus 10.4 percent) occurred more commonly with zoledronic acid than with denosumab. Toothache (not associated with ONJ) and hypocalcemia were more common with denosumab. The most common adverse reactions in patients receiving denosumab (in at least 25 percent of patients) were fatigue or asthenia, hypophosphatemia, and nausea, while the most common serious adverse reaction in patients receiving denosumab was dyspnea. The most common adverse reactions resulting in denosumab discontinuation were osteonecrosis and hypocalcemia. A potential for an increased risk for infection and malignancy associated with denosumab use has been raised by other clinical trials, but were similar for denosumab and zoledronic acid in this trial. A further discussion on the risks of denosumab in patients with advanced malignancy is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H454293264#H454293264\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Risks specific to denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85571978\">",
"    <span class=\"h1\">",
"     CLINICAL USE OF OSTEOCLAST INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated that osteoclast inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    or bisphosphonates reduce skeletal morbidity in breast cancer patients with bone metastases. The bisphosphonates have been incorporated into clinical practice for approaching two decades, yet several aspects of the clinical administration of bisphosphonates remain unanswered. Several evidence-based guidelines with recommendations by interdisciplinary expert panels have been published and help provide consensus answers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/16,17,23,41\">",
"     16,17,23,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608404370\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trial data, individually and in meta-analysis, has established that in women with metastatic breast cancer and clinically evident bone metastases, the use of bisphosphonates (oral or intravenous) reduces the frequency of skeletal-related events (SREs) by approximately one third when compared with placebo or no bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/16,23,42-47\">",
"     16,23,42-47",
"    </a>",
"    ]. However, osteoclast inhibition has not been shown to impact overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36,47\">",
"     36,47",
"    </a>",
"    ]. In addition, there is no evidence that the use of osteoclast inhibitors decreases the risk of SREs in patients with advanced breast cancer without bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Consequently, therapy with osteoclast inhibitors for the management of SREs is recommended to begin after the identification of osseous metastases and not sooner unless as part of a clinical trial.",
"   </p>",
"   <p>",
"    The efficacy of osteoclast inhibitors to reduce the incidence of skeletal-related events (SREs) was evaluated in a 2012 meta-analysis with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to placebo, intravenous bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      ) significantly reduced the risk of SRE by 15 percent (relative risk [RR] 0.85; 95% CI 0.77-0.94) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/47\">",
"       47",
"      </a>",
"      ]. The median reduction in SREs was 28 percent (range, 14 to 48 percent). This was associated with significant delays in median time to SRE, improvements in bone pain, and improvements in global quality of life. However, there was no difference in overall survival.",
"     </li>",
"     <li>",
"      Compared to bisphosphonates,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      was significantly more effective (RR 0.78, 95% CI 0.72-0.85). Compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      , denosumab was associated with reduction in the SRE rate and delays in time to SREs, and prolongation in the time to developing bone pain (in patients without pain at baseline). There was no difference in overall survival.",
"     </li>",
"     <li>",
"      A 2005 meta-analysis showed that compared to placebo or no treatment, the oral bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       clodronate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      ) showed a reduction in the risk of developing a skeletal event by 16 percent (RR 0.84 95% CI 0.76-0.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hence, osteoclast inhibition makes a significant reduction in the risk of SREs in patients with metastatic breast cancer involving the bone. However, this is not associated with improvements in survival outcomes. We reserve the use of osteoclast inhibiting therapy for women with breast cancer and evidence of bone metastasis on imaging studies. These agents effectively reduce the incidence of SREs, improve pain related to bone metastases, and improve quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85572580\">",
"    <span class=\"h3\">",
"     Role of osteoclast inhibitors for pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although osteoclast inhibition with either the bisphosphonates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    have been shown to decrease bone pain, bone modifying agents should be considered as an adjunctive therapy for bone pain control, not as a substitute for analgesics, radiotherapy, or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/19,43,44,48-51\">",
"     19,43,44,48-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32170?source=see_link\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Whom to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and others, including the American Society of Clinical Oncology (ASCO), recommend that osteoclast inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    or a bisphosphonate be considered in the management of patients with metastatic breast cancer and evidence of bone destruction on plain radiographs, CT, or MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"     51",
"    </a>",
"    ]. Starting a bone modifying agent in women with only a positive bone scan is not recommended outside of a clinical trial.",
"   </p>",
"   <p>",
"    For patients with metastatic breast cancer without evidence of bone metastases, there is no role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    or bisphosphonates, although both are excellent interventions to treat postmenopausal osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     When to initiate treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and others, including ASCO, suggest that therapy should start once there is evidence of metastatic bone disease (with evidence of bone destruction on radiographs, computed tomography [CT] scan, or magnetic resonance imaging [MRI]), even if the patient is asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608405085\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of benefit for monthly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    or bisphosphonates in women with osteolytic bone metastases is unknown. Drug administration for at least six months is typically necessary before an effect is seen on skeletal morbidity outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/45\">",
"     45",
"    </a>",
"    ]. Although prevention of skeletal complications and palliation of symptoms have been seen with up to 3.6 years of continued therapy, the fracture rate beyond two years may be no greater than during the first two years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/25,52\">",
"     25,52",
"    </a>",
"    ]. The risk benefit ratio of bisphosphonate therapy after two years of treatment has not yet been fully studied. In the phase III clinical trial comparing denosumab to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , the median time on study was 17 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are ongoing clinical trials investigating the long-term optimal interval between doses of bisphosphonate therapy in patients with metastatic bone disease from breast cancer. The clinical trial NCT00320710 (Optimize 2) investigates women with metastatic breast cancer involving the bone who have had long term exposure to bisphosphonates and asks whether a less frequent dosing interval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    may be as efficacious in decreasing SREs as the standard monthly dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/53\">",
"     53",
"    </a>",
"    ]. In this trial, patients are randomly assigned to zoledronic acid (4 mg) dosed every four weeks versus every 12 weeks in patients with MBC involving the bone who have had at least nine prior doses of bisphosphonate therapy. A slightly different approach to studying the interval of dosing is applied in the Cancer and Leukemia Group B study, CALGB 70604 (NCT00869206), which examines patients with metastatic bone disease from multiple myeloma, breast cancer, or prostate cancer who are beginning bisphosphonate therapy with zoledronic acid and randomizes them to either every four or at a dosing interval determined by biochemical markers of bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/54\">",
"     54",
"    </a>",
"    ]. A third study (NCT00458796), which is being performed in the United Kingdom, seeks to identify optimal zoledronic acid dose intervals using markers of bone resorption as indicators of osteoclast activity. Here patients with MBC involving the bone are randomized to receive zoledronic acid every four weeks or by biochemical markers of bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ASCO guidelines suggest that once initiated, bone modifying agents be continued until evidence of substantial decline in a patient&rsquo;s general performance status [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608405117\">",
"    <span class=\"h2\">",
"     Use of biochemical markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of markers of bone metabolism (resorption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deposition), such as urine NTx (N-telopeptide of type I collagen) to monitor the use of bone modifying agents is not recommended for routine care [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, three options exist when selecting an osteoclast inhibitor for the management of metastatic breast cancer involving the bone. There are two bisphosphonates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (the monoclonal antibody targeting RANKL) to chose from. All three agents are approved by the Food and Drug Administration (FDA) for the treatment of metastatic bone disease, and endorsed in guidelines from ASCO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      90 mg infused over two or more hours every three to four weeks",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      4 mg infused over 15 min or more every three to four weeks",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      120 mg subcutaneously every four weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     Clodronate",
"    </a>",
"    (administered orally) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (administered both orally and intravenously) are approved for use in metastatic bone disease outside the United States.",
"   </p>",
"   <p>",
"    There is no clear superiority of either oral or intravenous formulations of bisphosphonates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      (50 mg daily) was compared to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (4 mg monthly) in a phase III study, markers of bone metabolism were equally affected by both, but ibandronate was associated with fewer adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small study of patients with bone metastases from breast cancer prescribed either oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       clodronate",
"      </a>",
"      or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      , there was no difference in mean costs or average lifetime costs [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, oral bisphosphonates require precautionary measures to ensure absorption and to avoid gastrointestinal toxicity, and these may compromise patient adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/53,58\">",
"     53,58",
"    </a>",
"    ]. The dosing and gastrointestinal side effects of oral bisphosphonates are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also no clear superiority of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    . Zoledronic acid may be more convenient since it is administered over a shorter time period than pamidronate. Renal toxicity associated with both may be reduced by observing recommended infusion durations, optimizing hydration prior to bisphosphonate therapy, and avoiding concurrent nephrotoxic medications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      was compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      in a trial of 412 women with breast cancer and osteolytic bone metastases who were randomly assigned to monthly treatment with zoledronic acid (4 or 8 mg over 15 minutes) or pamidronate (90 mg over two hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/28\">",
"       28",
"      </a>",
"      ]. The 8 mg dose was subsequently reduced to 4 mg because of the development of elevated serum creatinine levels. The percentage of patients who experienced at least one skeletal event was similar (46 versus 50 percent), but patients treated with 4 mg zoledronic acid compared to those treated with pamidronate had a slightly but significantly lower risk of a skeletal event after two years of treatment (relative risk, RR 0.80, 95% CI 0.66-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another trial randomized women with metastatic bone disease from breast cancer to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      infused in the hospital setting or the community. There was a built in crossover in this study. Analysis showed significantly greater improvements after treatment in the community setting compared with the hospital, but there no difference in renal or other toxicities based on setting, with zoledronic acid being well tolerated in both environments [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a time in motion study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      there appeared to be a time saving advantage associated with zoledronic acid due to the shorter infusion time [",
"      <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the head to head comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    (120 mg subcutaneously monthly) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (4 mg intravenously monthly), denosumab demonstrated an improvement over zoledronic acid in the time to the first and subsequent SREs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ]. While denosumab appears to be superior to zoledronic acid with respect to SREs, there was no difference in overall survival or disease progression. In addition, long term effects of denosumab, the duration of dosing, and sequencing with bisphosphonates have not been defined. (See",
"    <a class=\"local\" href=\"#H608404691\">",
"     'Denosumab'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H608404370\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , the toxicity profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    appears similar for osteonecrosis of the jaw; it is greater for hypocalcemia and toothache, but lower for acute phase reactions and deterioration in renal function.",
"   </p>",
"   <p>",
"    An expert panel convened by ASCO to update the Clinical Practice Guideline on the role of bone modifying agents in metastatic breast cancer concluded that there was insufficient evidence relating to efficacy to support one bone modifying agent over another [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"     51",
"    </a>",
"    ]. However, according to the phase III data discussed above, there may be an advantage in controlling SREs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    for those with newly diagnosed bone metastases from breast cancer for whom therapy with an osteoclast inhibitor is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"     36",
"    </a>",
"    ]. When selecting an osteoclast inhibitor for the management of bone metastases, the decision for one agent over another may be influenced by availability, toxicity profile, patient and clinician&rsquo;s preference, convenience, and cost.",
"   </p>",
"   <p>",
"    At present, there are no data demonstrating the safety or efficacy of combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    with an IV bisphosphonate when managing bone metastases, and this approach is not recommended.",
"   </p>",
"   <p>",
"    Sequential use of IV bisphosphonates followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    was at addressed in a phase II trial that examined sequential use of an IV bisphosphonate followed by denosumab [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients were evaluated by uNTx, a biochemical bone marker not used in routine clinical management of bone metastases. The results of the study supports the efficacy of denosumab in patients with prior IV bisphosphonate exposure when there is a persistently elevated uNTx. However, assay for biochemical bone markers is not recommended as a component of routine care at present. (See",
"    <a class=\"local\" href=\"#H608405117\">",
"     'Use of biochemical markers'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85572324\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL OSTEOCLAST INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel therapies being investigated as bone specific treatment in patients with MBC include the Src (sarcoma family of tyrosine kinases) inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Preclinical data have demonstrated that Src regulates osteoclast function and is involved in signaling cascades important in the formation of the sealing zone between the osteoclast and bone matrix, which is necessary for bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/16,64,65\">",
"     16,64,65",
"    </a>",
"    ]. Dasatinib, an oral",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    inhibitor as well as Src inhibitor, is used in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Other Src inhibitors in phase II clinical trials include saracatinib (AZD0530). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cathepsin K inhibitors are another class of agents under investigation. Cathepsin K is a proteinase that is secreted by osteoclasts and degrades bone; it is also produced by cancer cells that metastasize to bone to promote cancer cell invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/54/8042/abstract/16,66,67\">",
"     16,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases in patients with metastatic breast cancer occur frequently and are associated with significant morbidity and mortality. Osteoclast inhibition has been shown to reduce the morbidity of metastatic bone disease, in particular skeletal-related events (SREs), which include fracture, need for surgery or radiation to bone, spinal cord compression, and hypercalcemia of malignancy.",
"   </p>",
"   <p>",
"    Although the osteoclast inhibitors, bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , have been shown to decrease SREs and improve both pain and quality of life, they do not affect mortality. There are now two classes of osteoclast inhibitors approved by the United States Food and Drug Administration for the management of metastatic bone disease in patients with breast cancer, the bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , and the monoclonal antibody to RANKL, denosumab. Other osteoclast inhibitors, in particular tyrosine kinase inhibitors that affect Src, hold promise as alternative bone-directed therapies for metastatic breast cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the use of osteoclast inhibiting therapy for women with breast cancer and evidence of bone destruction on plain radiographs, CT or MRI (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Options for therapy include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      (120 mg subcutaneously every four weeks) and the intravenous bisphosphonates, ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (4 mg over 15 minutes every three to four weeks) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      (90 mg over two hours every three to four weeks).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       Clodronate",
"      </a>",
"      (administered orally) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"       ibandronate",
"      </a>",
"      (administered both orally and intravenously), when used at doses and schedules for metastatic bone disease, are also options in countries where their use in patients with metastatic breast cancer and bone metastases are approved.",
"     </li>",
"     <li>",
"      For patients with newly diagnosed bone metastases from breast cancer for whom therapy with an osteoclast inhibitor is indicated, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      be considered as the preferred agent based on clinical trial data showing that denosumab improved the time to the first and subsequent SREs when compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Selection of therapy ought to be personalized taking into account the risk of toxicities, including hypocalcemia and renal dysfunction, as well as patient preferences, convenience, availability and cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there are scant data on the efficacy and toxicity profile of long term osteoclast inhibiting therapy, the risk of SREs continues throughout the spectrum of the patient&rsquo;s disease course. Therefore, it is generally recommended that osteoclast inhibiting therapy be continued, in the absence of intolerable toxicity, indefinitely, if consistent with both the patient&rsquo;s and the clinician&rsquo;s joint treatment goals. (See",
"    <a class=\"local\" href=\"#H608405085\">",
"     'Duration of therapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/1\">",
"      James JJ, Evans AJ, Pinder SE, et al. Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer 2003; 89:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/2\">",
"      Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/3\">",
"      Wei B, Wang J, Bourne P, et al. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 2008; 39:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/4\">",
"      Colleoni M, O'Neill A, Goldhirsch A, et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18:3925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/5\">",
"      Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/6\">",
"      Dawood S, Broglio K, Gonzalez-Angulo AM, et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008; 26:4891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/7\">",
"      Briasoulis E, Karavasilis V, Kostadima L, et al. Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer 2004; 101:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/8\">",
"      Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000; 89:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/9\">",
"      Coleman RE. Uses and abuses of bisphosphonates. Ann Oncol 2000; 11 Suppl 3:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/10\">",
"      Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/11\">",
"      Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/12\">",
"      Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17:846.",
"     </a>",
"    </li>",
"    <li>",
"     Ross AC, Taylor CL, Yaktine AL, and Del Valle HB. Dietary Reference Intakes for Calcium and Vitamin D, Committee to Review Dietary Reference Intakes for Vitamin D and Calcium (Ed), The National Academies Press, Washington 2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/14\">",
"      Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist 2008; 13:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/15\">",
"      Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/16\">",
"      Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 2009; 7 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/17\">",
"      Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/18\">",
"      Cascinu S, Graziano F, Alessandroni P, et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 1998; 6:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/19\">",
"      Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004; 22:3587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/20\">",
"      Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/21\">",
"      Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/22\">",
"      Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010; 95:4380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/23\">",
"      Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/24\">",
"      Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19:3383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/25\">",
"      Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/26\">",
"      Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/27\">",
"      Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 Suppl 2:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/28\">",
"      Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/29\">",
"      Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/30\">",
"      Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/31\">",
"      Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/32\">",
"      Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. Bull Cancer 2001; 88:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/33\">",
"      Mystakidou K, Stathopoulou E, Parpa E, et al. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. J Cancer Res Clin Oncol 2008; 134:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/34\">",
"      Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/35\">",
"      Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw 2009; 7 Suppl 7:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/36\">",
"      Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/37\">",
"      Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/38\">",
"      Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26:4875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/39\">",
"      Smith MR, Egerdie B, Hern&aacute;ndez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/40\">",
"      Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564.",
"     </a>",
"    </li>",
"    <li>",
"     Bisphosphonate Therapy for Patients with Breast Cancer Metastatic to Bone. British Columbia Cancer Agency Cancer Management Guidelines, available online at file://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Management/MetastaticDisease.htm (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/42\">",
"      Machado M, Cruz LS, Tannus G, Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther 2009; 31:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/43\">",
"      Diel IJ. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Support Care Cancer 2007; 15:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/44\">",
"      Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009; 6:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/45\">",
"      Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/46\">",
"      Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; :CD003474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/47\">",
"      Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012; 2:CD003474.",
"     </a>",
"    </li>",
"    <li>",
"     Cleeland CS, Patrick DL, Fallowfield L, et al. Comparing the Effects of Denosumab and Zoledronic Acid on Pain Interference with Daily Functioning in a Randomized Phase 3 Trial of Patients with Breast Cancer and Bone Metastases (P1-13-01). San Antonio Breast Cancer Symposium 2010.",
"    </li>",
"    <li>",
"     Fallowfield L, Patrick D, Body JJ, et al. The Effect of Treatment with Denosumab or Zoledronic Acid on Health-Related Quality of Life in Patients with Metastatic Breast Cancer (P1-13-05). San Antonio Breast Cancer Symposium.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/50\">",
"      Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 24:4895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/51\">",
"      Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/52\">",
"      Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19:3434.",
"     </a>",
"    </li>",
"    <li>",
"     Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer file://clinicaltrials.gov/ct2/show/NCT00320710 (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement file://clinicaltrials.gov/ct2/show/NCT00869206 (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone file://clinicaltrials.gov/ct2/show/NCT00458796 (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/56\">",
"      Body JJ, Lichinitser M, Tjulandin S, et al. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann Oncol 2007; 18:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/57\">",
"      Romanus D, Iscoe N, Deangelis C, et al. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Support Care Cancer 2004; 12:844.",
"     </a>",
"    </li>",
"    <li>",
"     Mangiapane S, Hoer A, Gothe H, et al. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 2006; 24:18S (abstr# 18623). (Available online at file://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/18623, accessed November 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/59\">",
"      Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/60\">",
"      Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/61\">",
"      DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone file://clinicaltrials.gov/ct2/show/NCT00410813 (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis file://clinicaltrials.gov/ct2/show/NCT00566618 (Accessed on March 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/64\">",
"      Miyazaki T, Tanaka S, Sanjay A, Baron R. The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 2006; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/65\">",
"      Destaing O, Sanjay A, Itzstein C, et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol Biol Cell 2008; 19:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/66\">",
"      Le Gall C, Bellahc&egrave;ne A, Bonnelye E, et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res 2007; 67:9894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/54/8042/abstract/67\">",
"      Le Gall C, Bonnelye E, Cl&eacute;zardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008; 2:218.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 763 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8042=[""].join("\n");
var outline_f7_54_8042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BONE METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Skeletal-related events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CALCIUM AND VITAMIN D SUPPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H608403970\">",
"      BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608404042\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608404108\">",
"      Complications of bisphosphonate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pamidronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Oral bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H608404691\">",
"      DENOSUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85571978\">",
"      CLINICAL USE OF OSTEOCLAST INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608404370\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85572580\">",
"      - Role of osteoclast inhibitors for pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Whom to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      When to initiate treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608405085\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608405117\">",
"      Use of biochemical markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85572324\">",
"      INVESTIGATIONAL OSTEOCLAST INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/763\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/763|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/42/19118\" title=\"table 1\">",
"      Bisphos trials MBC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_54_8043="Interference with 5 HIAA";
var content_f7_54_8043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Substances that interfere with determination of urinary 5-HIAA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Falsely high values",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tryptophan-rich foods: avocados, pineapples, bananas, kiwi fruit, plums, eggplants, walnuts, hickory nuts, pecans, tomatoes, plantains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs: acetaminophen, coumaric acid, guaifenisin, mephenisin, phenobarbital, reserpine, acetanilid, ephedrine, methamphetamine, nicotine, phentolamine, phenmetrazine, caffeine, flourouracil, melphalan, methocarbamol, phenacetin, mesalamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Falsely low values",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs: corticotrophin, ethanol, imiprimine, levodopa, MAO inhibitors, phenothiazines, aspirin, isoniazid, gentisic acid, methenamine, streptozotocin, heparin, methyldopa",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     5-HIAA: 5-hydroxyindoleacetic acid.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rosen S. JAMA 1988; 260:1606.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8043=[""].join("\n");
var outline_f7_54_8043=null;
var title_f7_54_8044="Oncogenes thyroid tumors";
var content_f7_54_8044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oncogenes and tumor suppressor genes in thyroid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neoplasm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contributory genetic abnormalities",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic abnormalities of uncertain importance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Benign neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autonomously functioning thyroid nodule",
"       </td>",
"       <td>",
"        TSH receptor-activating mutation; Gs-alpha mutation decreasing GTPase activity",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nodular goiter (colloid nodules)",
"       </td>",
"       <td>",
"        Many nodules are monoclonal, but precise gene abnormalities are unknown",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Follicular adenoma",
"       </td>",
"       <td>",
"        RAS mutations",
"       </td>",
"       <td>",
"        c-myc and c-fos overexpressed; PTEN abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Malignant neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papillary thyroid carcinoma",
"       </td>",
"       <td>",
"        BRAF (V600E) activating mutation; RET rearrangements (RET/PTC); NTRK1 rearrangements (TRK); 14q13.3 and 5q34 (pre-mir-146a)",
"       </td>",
"       <td>",
"        Tumor suppressor hypermethylation; miRNA upregulation; TIMM44 mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Follicular thyroid carcinoma",
"       </td>",
"       <td>",
"        PAX8-PPARgamma1 fusion; RAS activating mutations",
"       </td>",
"       <td>",
"        Tumor specific LOH throughout genome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anaplastic thyroid carcinoma",
"       </td>",
"       <td>",
"        P53 mutations; BRAF (V600E) activating mutation; Exon 3 CTNNB1 mutations; ALK activating mutations",
"       </td>",
"       <td>",
"        PIK3CA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medullary thyroid carcinoma",
"       </td>",
"       <td>",
"        RET activating mutations",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8044=[""].join("\n");
var outline_f7_54_8044=null;
var title_f7_54_8045="Etiology of dystonia a";
var content_f7_54_8045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dystonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       I. Primary dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       A. Sporadic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       B. Inherited (all atosomal dominant)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Classic (Oppenheim's) dystonia (common in the Ashkenazi Jews, DYT1 - 9q34)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Childhood- and adult-onset cranial-cervical-limb dystonia (DYT6 - 8p21-22)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adult-onset cervical and other focal dystonia (DYT7 - 18p)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       II. Dystonia-plus syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       A. Sporadic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Parkinson disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Progressive supranuclear palsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Multiple system atrophy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cortico-basal ganglionic degeneration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       B. Inherited",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       1. Autosomal dominant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Dopa-responsive dystonia (DRD) (DYT5-GTP cyclohydrolase I 14q22.1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Dystonia-Myoclonus (alcohol responsive, chromosome - 18)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       2. Autosomal recessive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Tyrosine hydroxylase deficiency (chromosome - 21)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Biopterin deficient diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Aromatic amino acid decarboxylase deficiency (dopamine-agonist responsive dystonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       III. Heredogenerative diseases (Typically not pure dystonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       A. X-linked recessive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lubag (X-linked dystonia-parkinsonism, DYT3 - Xq13)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pelizaeus-Merzbacher disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lesch-Nyhan syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Deafness, dystonia, retardation, blindness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       B. Autosomal dominant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rapid-onset dystonia-parkinsonism (RDP)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Juvenile Parkinsonism-Dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Huntington disease (IT15 - 4p16.3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spinocerebellar degenerations (SCA1- SCA8)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dentato-rubral-pallidoluysian atrophy (DRPLA) vary degeneration with Wernicke's encephalopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hereditary spastic paraplegia with dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Thalamo-olivary degeneration with Wernicke's encephalopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       C. Autosomal recessive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Wilson disease (Cu-ATPase - 13q14.3)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neurodegeneration with brain iron accumulation type 1 (NBIA 1) (Hallervorden-Spatz disease - 20p12.3-p13)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ataxia telangiectasia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jankovic, J, Fahn, S. Dystonic disorders. In: Jankovic, J, Tolosa, E, (Eds), Parkinson's disease and movement disorders, 3rd ed, Williams &amp; Wilkins, Baltimore 1998. p. 513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8045=[""].join("\n");
var outline_f7_54_8045=null;
var title_f7_54_8046="Improved BMT outcomes in AA";
var content_f7_54_8046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Improved outcomes with bone marrow transplantation in aplastic anemia when using antithymocyte globulin in the conditioning regimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 221px; background-image: url(data:image/gif;base64,R0lGODlhJQLdANUAAP///4CAgAAAAP+AgICZ/0BAQMDAwCAgIP8AAKCgoDAwMBAQEHBwcNDQ0PDw8LCwsFBQUAAz///AwP9AQGBgYODg4JCQkEBm/8DN//+goP8gIP9wcP9QUP9gYP8QEFBz/yBN///Q0P8wMP+wsKCz///w8LDA/3CN/xBA/2CA//+QkDBZ//Dz///g4NDZ/+Dm/5Cm/7+Mvz8mv4BwcH8Zf0BNgIAwMGBmgH8AAI8mgL9NgCAyfwAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAlAt0AAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1dbX2Nna29zdUQ8BAQ9UCQUNTgUM3uvsWw4KAgXwAVMGARVO8e2RFRYBCQ4ApMMycEm/ABbONTCAT4gBAw4MnAOwMODChwH3ZQkgQB3FBxUCGAAQcuS/BgFQjrS38B44fAkCRIRQoIAFIfo0NkogoKe+/5xW/i3hGe+AAAMWBFAQUkEABAM5CxwV6LOjzitEC6QEAJVeVwACFvRsCgEABAEhj/K8ueAAgAAUAkhNALbA1UVNF4xEWddCAQoBT9JzwODvxH9+Ab+ly5WC4SF5Jz5o0FRAYAEJoNqlOlIqRAoC6N2lEkBsz8yhuaYWoGCIVAcL7HKEuEBBg9QOLECYV3d0oqQeh/RUYHRp2J4AFCwIoBzf8OK9oSqQKxoAcCNn6R5YoPpAOKOdp+b1LSVjAwbxvn4FyhM03dkAQIPGp9xCUnpAyRPiWB2nXQc/tUaRVQ8IcJM+ANqlz1kNNfTWaj2NVKA5VkFV1VSe4SSAflDIlf8ZaCmFJddqmwEAYFiXSdjTZgIcYAB6+JXIoSA8legciwpuph6J/vUm1RETcgXPSACIJdU5mgmRYYZNuTVjEwZI1aJo6B0AYm9DyCcEfAAYxVhWPD45iFFa0YTlTyW2ZcBZ5+SEpnVK2dMfPBQYMKQQ6LHmUFQYGvgAPOOIKaguFZzV4oE4YkkRPAcw5maOWxq1QKBCOECBWAtA0OBpe262pE8KUDroqKSWauqpqKZaigMxicbqPxmpKutdDRjpJDxSCTjrrvsYNREABZZ1lqi8FqvNbQcYVRZ/D/ZnrBwSDfEqQEOAY4GDz0IinZ2YMcvsEHKKlG0aKAGFq54AoKf/3ALYjsvIbbKFdh16N4EbjlbuniHlZsGaJcADAHJ3Xb6OGPXnUU0aYFS7WzpLcBhJNttskhHbG464DwfSADwLfGlUo0iEkzEZEXsbGsX5cXVxATewMPIkIr8McU7zGnhba/2GvEMEH2Ag8yMx/9xFA0kpAFHCC3f5b3ZJhMNCCgQI3UjQUmshZYQAJPAxYxuHFdwRIhMQddWKUE02HWGPffYhZq8dxwwzAEDABWLXLbbPbleRmRAPEOtF23m7MQMOGWBgd910B04FvunK+AXgiq8RgA0IZHCE2JFDYWFVZYkBeeZohJNB5UbMffjpqKeu+uqst+7667DHLvvstB+O/ze5BbRVEwS/gvE56GaIvMEGRhhe+/HIJ6/88swrf7saewfv8BMSDGD9ABIAP4XI1mtvRQM01fT149M7McAE1qPvfRTcD7A+FUb55Pjf5TfRPQD3Z0uZEPt7Tk/+74OCU87wuyXcD4DGYpxcxsA94gUwChAYn/+qcED3PasBuTtATWLDQHqMwAOWe+ATLlWTgoShgEqoYLY215NJdVAIIfBAB0SIjqrMrwsoTIIKx8UAxpQhaCUQAQdKQEO01S8J1TufBZWYPf09JFoTHEIJOCACIhYRCYQxBwT8hsMjIkGJ2BNC9dQnRus1MVV5WtELi9ABD4TgikcwlAEo0LkTev/xCBwIYRHy14EJkDFVIgqHD303vQx4YARwLIKBCmCPG3Ihh0WYwBmJkD9JItBU3iFg+TZgwUTi5AGMLEAdCSkFSR4hfwhowSVLVZgn9o58X+ykJy/VFsysEQoIsOIeLdgCBOBPlqe6WsroF0tPSussC5AgMaPgy1Ny4I0SmMAvZdUqQd5yj+i73vUm+T5wkGQrUXxCCZppBAlwwAMe0MAMwWjGU70EnHZEQhK1qUQaZlIgo4QlFKK5hBCoIHvzrCcrIwSBpYTTfsBc31Te4sgtQHII/JzCKp+0AAoYbYEHZQI76cnRjnr0o9ZDJKqs5IB3GDSeUMgAB6gw0RkdhZH/jrkmEwIK0pra9Hod0ECqOOITIqHUCdFMqPmE+iR5HOAs9frpHTSgR1OVY4tkeCgAOsABbj6hpRyq1XBixYVwMQ4PGdDpqRIwSJkuQQRWvSpRxQTFL3j1jm9g6qnMJD1cWgGr+tkNSZZj1jqEdawuesgrl9kECYjgrtnUZlrv8i88NVQLUmWDOm9K2cpa9rKYzaxmt8kGYT52I3AVwgZmWAWaCpRDjW1cX+swgs269rWwje1mF0uGagolo0gYgQY0INIt4HUfEEgmvVZrzCJE5LhRWEhDpsVVIuRwAKTtwm/b0YD4KaC5hC0uEohiJ2UmQauiOZeuivDctd7VvFdp/ytutUuEAxCnkVCAR2r6NSywwXW6UhheUT/7yNAm8qUv4u8QSgMjiX3LIfe6L3qpMLqm+gajP/QvHK00nWQ64TbgSI3J+iOnr6bQgV7QL4fQU0LvOlTCVyxQCxkWsgshxCrDNUIO5foF/HrDs8RlL0UQwmIkVOAh8qkA0tBiXyb8FQw2zlhkU8xjKXxLay0q64DvSOMaL5gdXVNYUkmp4yOkcQGD7eISjozkK69jXQHOsXadYoAHZErNHDAzSxPLUdpm41+MhDCXu1wEo21JwEHxoinDYNrr/XEdC/DLA6yk5uIW5l5akfKJl5BKNiRZGjzF2nq7LEw17vkIvWzDpf+l4ReoNtqYF3miesWMRGlaWs7UiEiYs8tnyR0RuqKGtTSIwhrssrrWbPjdqH2r62i0JQDoOemngZ0GYRd7CyqILqKJVJhTM1ufxWSDYd0ggSa2QAItAMAEQEyFEEzAwUgwN7qjMG4CMgDIT5k1aK9dhDn6dNlF4KQbyLkGBDRzAAhw3wDWLYGAN0GVdoaowaMA8CYO/AkT4LcUOj3MSdN7CLeJh7yx8LtBswGtbfC3EAAu8BCqwI8baEEHEKC+EmxgAh14I/4yEIIBIFwIKh13CczpRxUAoOCyVOUIXi7Sl8M8BC2IeAcs93AAZKDnI8/AyTuwcw0EPHsj4ADMEz7/BNtaE9/0toekIXtEj6+BqmFUg7/TZ3CWTxUBnESrCBCgAWmKwAMDuHu4EeABfwMdfwiIswaq14HzVe7vCtdA3hHwRsVvIJ0hsLoIiOf2DcCdAwjwub9FYPWl9/3co4tznO+w5CK+c+PzToLZ1TDGZ2PB37BvuzQxH2eAGjwEcAfACDIPAAQc9ucGT6cQSkB8FVDx6gsXo8F37z4JvLzvgG+i29NpPbe7fZzSjLgQVOD7poNB1URirhJKL8I8rUnZ2D7C6tcw7Nf/W/YAKEEH5o6AEfz9/vAHvvvcPoS7q4D72JN8+qd/u8cBIzB30ScE1qd41mM5/Od22jdyEZd7/2BwIUIgXuOHYkVUURcFaFXQcVxHBu13BSIHePsnTR3wT5b3T4GHSOlkTozXe672d5j3T1VFd86HfLJUcB1gWIxHcrrlSySXPW6HediTASeogNlXf/60ARIQemEQIQ8BLANUX0TwVhcHYDG1aUKwfmowglZQgiQng/jTdx7gQBHnAQAQAnNHY/z3d/LXdxrQAqPDcjpIBAVndSAUf21odQDQAla3UtfXRnyXhGT4QZkXhIGnSxdGLUywIk9hYKlxhSujgTRkVEiVY16YBhsVgpGAeHoAFcvha0QAAXARFmlBDwcmY5YoQlrVazmmATKXBBjwPF8QUO3WCaAYitRRQ/9IAWMG0jSt+EA/9kSkaHFIIHGXozZlEFHYABGaMx2gsQAOMGQ99hbDGEAKUBYOwGhc2HtMgDlnEHnakDsUgHqQIV+2IQRQBjLCmIVEomfpZwTKWDrMWAb1OA0JIF8HYAHHmHrXlmhCAAH5RGtFkI9EII5nIIvbYACmMYnzWGugoQDwMHbIeAQIOQQKaQabGA372BNWokFKBWyW4jVRdUT5aDymkwYv107VIBUUQCno+IHZeHHbg5JIYDpzQzd2Y4tekESHJg3QWFf0Bj4lRlzkuIxCoJJikzhlAIbA0ENC4A/Wlkjx42kjiYeuZo85eY9hAJW9EBEKUCdr4oGkUZP/ClWQWQlRW1kEG5mQXllm1MBCPYF+BslnEaRJrdaVfPmUrgcMIaFB4eCPVQlHJCQ+xBVRTLmSl0M3PukFYOkL/RNhF4djXBhRKfABtoMEhuOUYrBRshWamuWJeGAOhXGU32iTSnAQhGkiMeGIrLiXAHABj5kEb3mLopmbmhWUgfBSNlSYV5Rl/fgEVyMgGFhk8uRqEeAyT3CbrBCZmEB+D4Rm1eYEANONR0FfqUVe9TMAxOMCIBAFzrkK0MkG4CdYwFlEeAZfUbAwG0aJvVhMJnAB4hmX5PmXcXAhWAl2XZZoBbBodrkE1/GeFuNhuyQ39mmbPIk6tQkK5WlrF/N1/2vZZZm2UE6QbFMJjFs2ZUlQeLNpAlGwmHbjmaXwoJUgnQ9UalyUBGfhHSJhjchZBGHFWwAAAi6wBePpoPgJB6ZZQibEn6q5BC6WNVsTMs6iWzTGAhHABTn6CSaaBr4pP+n5QD6KmiM5WkSAAfSJownqpDuqCSjqPfpZcf0VSZMEAynApF3qCaApmqR5BVlkaqkZpBcJAAw5BB8AA2qKCoUmW7wJBsK0onVaa7lxMRZJdgdZBCjwAky6oKnToLXwpEiAGwpgljd5cYayn+mXlEsZnlwgoodDorogqUfwn382pSLUES+FlktANc4oN2mKBk1KC6RKBDVBHDVxVG5Vif/wyC7ymF3eSQQrAKKyuqazUKvCoZ+W6gRYSG8dAwHbsazs0x/5o6TMeQazeqx05lFvKgdhuj5kVStgdk15NAQmsAJqkK2y0Kf01K1IYJSIOafG9I/Z5XFQk67Gqg3ypal3yWkKAJsH5XEgAKlgoK53xhPxwaoZeHFpVCfXlEtC8AIosAYGiw1H4SLVOaFd5gCgRKYX2UwscAIfQLGOSgAEWw3eARoDJK+edB7xE6BlOnwIgAEfwDMn+wWLKarb0AAN4AAESa8cp7DAIxUHwAAzeQVBE00pcALXCgcVqwYvAAMEQAJNawcXcAJnIGuUSW8WIKiEFU0rcLPYmq9rQAL/EXC2EbClXpC2U4ABETA2U9ucESC2RsBr14WqD5RF4OO1AKlSS0oHOtk8tOOTLxABKOAzLhA1cSs3JMC4ieu4UcMCc/MBIPoCBGACJ5A4ZgsCBMCoEXu5mUusmXsBKXCjKZC2itu4AECzV+syUwsDpMsCL3ABEZACjWsCH0C6N3tsGMqyiSRHdHRLA6AD6EoHoCq4rqOzMBABWEsEbAsAbGu4Zwu9KDC9K4ACBLACEeACbpu21UsCJ2C4F3CjSxkBnKu9N8q5J4AC4am9IECfbGsCPBO+I3u2KwACtQueEbACJ2C2mqmZTaAXjoW3AbRI7PlTA5ADsUoKt0kAb1sE/88bvcULvcXrAqh7uib7wPIbNc87BG4bNRu8uplbvav7wNBLnzUrNvh7wgCgpPTpwD6zvCuwuEoAZO82R2oZs9e2nqIkvDRAtphwm2artowawfCrts/rtgtaiw/8wSycpU38tvJLudpbwmPDtrRrN0/MtjAsBHNzts2bBGMqrR0itKBDS17iw0B8Cc6Jv3STuwBQvSdwukc8BB2MAihAAhgAA3ocxRw8sJ5bwimAAejrwJe7wm5LuSy8vD1jAmlqxHLztnt8Ahjgv60aoRIKpOzlsyYpvDJArAwcly9Qs+arpySAx+Fbx0LQwS5AyiBgAk7sxA68vR5svobbuCzgvv8rPJuG+8QEgL88s8X0+QL4S7nA/AFVGwff6j08q5cjJwN0y8ZrTAZOfAecbGEE/D414cz4A82m8LTUbMJ2IBXyAJGarF1/ws0D4M2lAM6ekFoZe87FZZkIvJzfPM2ewFc+m8ODymenGa/1fAqBK7jR/AdptJ3yTKcAOQB/WwrHmzw6qwgqepL0hh58tbX409DE4M59QFbcXGsqpmm3FAMTvNEli7y1U9BxRMaXymwBcAAldU8jrbbE8NAoHTsqXbeBtWr9ql3M8RBjydO/FgM0rTj0nNBwVKH8CgXiF6NEDTy2dagAWWvlUKUm1gTHGZteHMaRI9RR0NRGqtBWoJ3/XBQ0HJ0v77DU8RUP6BLWYk0aGmbOHaYV4VADNYDJeJ3Xer3XfN3Xfv3XgB3Ygj3YhF3YfH1vU8ATFGlLVEDW9bYydG3Ykj3ZlF3Zln3ZmI3JiL0fcc1hkJbZg10ToC3Yoj3apB3Zpu3XpR0Om80+xjmMBGoxcoHaqb3Xq13btk3buJ3Xt73ben3brS0INbOhDdMGy3yWb3DcyO1QLiqYUt1iqmjO3GncZjytbqDcy80IMKrVtkbdyV3d1u1QyjoFw/2OwQbeT4DdTobeZfwI7Th26t3e5/3d123G4WKoU7DdMaoG8Z3e7O0E/S3fmjCF5hncZUDgbYDga6DgdPDe/zVs4CQD4WPA4GlA4RUu4W+d4Rq+4Rze4R7+4SAe4iI+4iS+B2B9BqwJtGCgXG3wKv+9BK/SmoFw4maQ4mzA4mzg4jkeEzJeCVmtL6CyBuB147ayBmktFdQoCD9uBsUp5GLx4kqgVQXgJGlw5ChiCY6NBtcJHmogX1CeBL6S4HqSIYCQ5Wew5RZ6Bl7OBmFunmOe5pIQ22mQNKGTTNJtBsiiLEYOD8QBs3og52hA5wRk519+BHm+slXO5954op29BgNzBhi2imewLRWpBpZSS3cLCIBuBo+O5/8i6WZA6YyNBpduFJlOCeWdBr0bOkNKLvoA6mRwH/5S6FyQ6miw6v8E1OpoAC8Skwayfha0Dgf6bQYtytpoUIxBtgYGcydpoNjc8tx1MOxlUOwYU+NAphTXKAbLDudl4OyVbgkODqVVEezOded4zjHQ/gUMIBYyDQjhjga6zurkTgRd0zFssO5TUuL6vu/83u/+/u8AH/ACP/AEX/AGf/AIn/AKv/AM3/AOvw8P0RA4HgagZA6WMNvCEPH8wxBjUPFHiwgYj2kIsgBJHgZNMR1NwdJ+wBOm+BW+wBH/QfIqXgUnfw8eqwgsLxLmngzYmWE34QByYWqneY4q0wB74xfpgC1Dfw6gUQBkNSUwURM3URIPMEj28AA/6yGO9RgskRldLyE0MfX/4qAy+ECVRABKceEVKZEZFeAY6VCNMDlH8TDvldDzHPHzQR8oS1/0Ry8+Sl8TRN/0T+8dUW8T39RmVi8OWe/0W0/0X//1wBL23zQO9lD2zoL2IvP1bS8+cB8nTU/3plAgpn6BywEP5+Ad6+4WHPHkoMEAP91eyNYWydEiDGDRptkRSCWK+bH6HKMcRIb6sr/6oSH84uAU6KEOtREfBgIgo1Qg02EUD/LkUXKK52jqHymSviD66KIczCEApx/7qn8cp+j6fjYEwO8WjFL7YXH7DJD7xyEjvB8Wvo8P5x/9wy/+wXL8RdIaoAEEFocAAjACHgJF4CAABAQLQcBQCFAE/5RGU5FQCA6F45hcNp/RafWa3Xa/1wWBoAFoCKzYAMDAKEifBB6MIIioyPr+nAymjPCMFg4CoAoYGcqgDAAeM/n8AKEGA0ULHQAUFgCwHBYUCpISxuQqAORGjxIo5MQ6GffggIOFh4nV5Ojs8K4aE0EFCQ01x5oXGzfFACIn8SwxBTQ5vz0Vb8tLT1NXW18FYo9ma51CcXXDNX2L8/X3+YcZsf9NopIEwoMvgaQ5oPDlmRGCBqv9erRJ0qQE+Mh0svfwYCeERmzFA5BAAIN2WQSYeudEpEeTDP59xNiPZk2baGLyUTbJAEd54gAoZCgKCRGIOiViAyPworUxGnl98//5kWpIWyRNklwli6UtlyVj9nJ6k2xZszgnZltw0UICKAEeNKFKwUIfARaOvI0b0dEBAxUKUXE7M684e3rlevRoYQrBoHOKzFFAxiTcxEDlPCAZ9Z7Rs59Bw8mplq3bxpel0bWL1whivhT/BjYweGxrw5xdU13cmMjj3pIpn/4pLfNmmZ5DJ1eeb3SDQmAeOPhyAHVrKQsuHZEORi5GKHQUXqdS+6O97dSH25YGgIEUCCoL4Y1PxoEc9FQbSNlVNcpy//6be+6A6Kar7onrsjPivO6s+a6B8KIY75enbkNowfSoYs89+O4CYL4x6uMOw/zwsAek/v5LUcUVWdSngoukEmilxRlprNFGMl6cTcYbeezRxxtJJKKOH4ks0shhgoRgyCOZbNLJJ6GMUsopqazSyiuxzFLLLbns0ssvwQxTzDHJLNPMM9FMU8012WzTzTfhjFPOOems08478cxTzz357NPPPwENVNBBCS3U0EMRTVTRRRlt1NFHIY1U0kkprdTSSzHNVNNNOe3U009BDVXUUUkt1dRTUU1V1VVZbdXVV2E9NAgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of chronic graft-versus-host disease (left) and Kaplan-Meier estimates of survival (right) in 78 patients with aplastic anemia receiving HLA-identical bone marrow transplants and GVHD prophylaxis with methotrexate and cyclosporine; 39 of the patients were conditioned with cyclophosphamide and ATG (current patients) and 39 were conditioned with cyclophosphamide alone (historical patients). The newer regimen was associated with a significant reduction in chronic GVHD and a significant improvement in eight-year survival (92 versus 72 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Storb, R, Leisenring, W, Anasetti, C, et al, Blood 1997; 89:3890.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_54_8046=[""].join("\n");
var outline_f7_54_8046=null;
var title_f7_54_8047="Contents: Nutritional issues in children";
var content_f7_54_8047=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Nutritional issues in children",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Nutritional issues in children",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cystic fibrosis nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29095\">",
"           Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15754\">",
"           Cystic fibrosis: Nutritional issues",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food allergy and intolerance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/32/5641\">",
"           Lactose intolerance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammatory bowel disease nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24693\">",
"           Clinical manifestations of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/46/2794\">",
"           Growth failure and poor weight gain in children with inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/6/43113\">",
"           Nutrient deficiencies in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41722\">",
"           Overview of the management of Crohn's disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/34/4650\">",
"           Treatment of ulcerative colitis in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malnutrition in developing countries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32248\">",
"           Malnutrition in developing countries: Clinical assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/4/38983\">",
"           Micronutrient deficiencies associated with malnutrition in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/61/9178\">",
"           Severe malnutrition in children in developing countries: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Methods of nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11529\">",
"           Enteral nutrition in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/47/32505\">",
"           Infant benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/1/32794\">",
"           Principles of medication use during lactation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/7/27765\">",
"           Discharge planning for high-risk newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27591\">",
"           Fluid and electrolyte therapy in newborns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23912\">",
"           Growth management in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/50/27434\">",
"           Parenteral nutrition in premature infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28631\">",
"           Dietary history and recommended dietary intake in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23912\">",
"           Growth management in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36487\">",
"           Indications for nutritional assessment in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/55/22391\">",
"           Laboratory and radiologic evaluation of nutritional status in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6760\">",
"           Measurement of body composition in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/14/31976\">",
"           Measurement of growth in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/4/38983\">",
"           Micronutrient deficiencies associated with malnutrition in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional deficiencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14538\">",
"           Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23782\">",
"           Physiology of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29753\">",
"           Zinc deficiency and supplementation in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional requirements",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/8/19593\">",
"           Approach to enteral nutrition in the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40040\">",
"           Calcium requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23735\">",
"           Dietary energy requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/6/23655\">",
"           Human milk feeding and fortification of human milk for premature infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37816\">",
"           Neonatal hyperglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/28/458\">",
"           Nutritional composition of human milk and preterm formula for the premature infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39226\">",
"           Overview of dietary trace minerals",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/14/21736\">",
"           Overview of vitamin A",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28871\">",
"           Overview of vitamin E",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15960\">",
"           Overview of vitamin K",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28650\">",
"           Overview of water-soluble vitamins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/38/28266\">",
"           Vitamin D insufficiency and deficiency in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obesity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/11/8378\">",
"           Clinical evaluation of the obese child and adolescent",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/50/37674\">",
"           Comorbidities and complications of obesity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/5/32858\">",
"           Definition; epidemiology; and etiology of obesity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18378\">",
"           Management of childhood obesity in the primary care setting",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Short bowel syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/45/29400\">",
"           Chronic complications of the short bowel syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26778\">",
"           Management of the short bowel syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30601\">",
"           Pathophysiology of the short bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific diets",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16778\">",
"           Adolescent eating habits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42967\">",
"           Fast food for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/9/9369\">",
"           Organic foods and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8266\">",
"           Vegetarian diets for children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-83DA152751-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_54_8047=[""].join("\n");
var outline_f7_54_8047=null;
